# EDGAR Filing Document

**Accession Number:** 0001776738
**File Stem:** 0001776738-25-000052
**Filing Date:** 2025-11
**Character Count:** 168760
**Document Hash:** e4fd6bc8f364eb6185801ee4e625b2bc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001776738-25-000052.hdr.sgml**: 20251110

**ACCESSION NUMBER**: 0001776738-25-000052

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 86

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251110

**DATE AS OF CHANGE**: 20251110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cannabist Co Holdings Inc.
- **CENTRAL INDEX KEY:** 0001776738
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE PRODUCTION - CROPS [0100]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 981488978
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56294
- **FILM NUMBER:** 251465679

**BUSINESS ADDRESS:**
- **STREET 1:** 321 BILLERICA ROAD
- **CITY:** CHELMSFORD
- **STATE:** MA
- **ZIP:** 01824
- **BUSINESS PHONE:** 2125543424

**MAIL ADDRESS:**
- **STREET 1:** 321 BILLERICA ROAD
- **CITY:** CHELMSFORD
- **STATE:** MA
- **ZIP:** 01824

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Columbia Care Inc.
- **DATE OF NAME CHANGE:** 20190514

?xml version='1.0' encoding='ASCII'? cbstf-20250930

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

_________________________________________________________

**FORM 10-Q**

_________________________________________________________

**(Mark One)**

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2025**

**OR**

□ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from __to __**

**Commission File Number: 000-56294**

_________________________________________________________

![Image 2.jpg](cbstf-20250930_g1.jpg)

**THE CANNABIST COMPANY HOLDINGS INC.**

**(Exact Name of Registrant as Specified in its Charter)**

_________________________________________________________

---

| | |
|:---|:---|
| **British Columbia** | **98-1488978** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |
| **321 Billerica Rd., Suite 204** <br>**Chelmsford, Massachusetts** | **01824** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (978) 910-1486**

_________________________________________________________

Securities registered pursuant to Section 12(b) of the Act: None

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | □ | Accelerated filer | ⌧ |
| Non-accelerated filer | □ | Smaller reporting company | □ |
| Emerging growth company | ⌧ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes □ No ⌧

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes □ No □

As of November 4, 2025, there were 497,455,422 shares of common stock, no par value per share (the "Common Shares"), outstanding.

**Table of Contents**

---

| | | |
|:---|:---|:---|
| | | &nbsp;&nbsp;**Page** |
| <u>[FORWARD-LOOKING STATEMENTS](#i50d87a5ec62c4d118a84439d43ce578c_10)</u> | <u>[FORWARD-LOOKING STATEMENTS](#i50d87a5ec62c4d118a84439d43ce578c_10)</u> | [2](#i50d87a5ec62c4d118a84439d43ce578c_10) |
| **[PART I.](#i50d87a5ec62c4d118a84439d43ce578c_13)** | [FINANCIAL INFORMATION](#i50d87a5ec62c4d118a84439d43ce578c_13) |  |
| [Item 1.](#i50d87a5ec62c4d118a84439d43ce578c_16) | [Financial Statements (Unaudited)](#i50d87a5ec62c4d118a84439d43ce578c_16) |  |
|  | <u>[Condensed Consolidated Interim Balance Sheets](#i50d87a5ec62c4d118a84439d43ce578c_19)</u> | [3](#i50d87a5ec62c4d118a84439d43ce578c_19) |
|  | <u>[Condensed Consolidated Interim Statements of Operations and Comprehensive Loss](#i50d87a5ec62c4d118a84439d43ce578c_25)</u> | [4](#i50d87a5ec62c4d118a84439d43ce578c_25) |
|  | <u>[Condensed Consolidated Interim Statements of Changes in Equity](#i50d87a5ec62c4d118a84439d43ce578c_28)</u> | [5](#i50d87a5ec62c4d118a84439d43ce578c_28) |
|  | <u>[Condensed Consolidated Interim Statements of Cash Flows](#i50d87a5ec62c4d118a84439d43ce578c_31)</u> | [6](#i50d87a5ec62c4d118a84439d43ce578c_31) |
|  | <u>[Notes to the Condensed Consolidated Interim Financial Statements](#i50d87a5ec62c4d118a84439d43ce578c_34)</u> | [8](#i50d87a5ec62c4d118a84439d43ce578c_34) |
| [Item 2.](#i50d87a5ec62c4d118a84439d43ce578c_97) | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i50d87a5ec62c4d118a84439d43ce578c_97)</u> | [23](#i50d87a5ec62c4d118a84439d43ce578c_97) |
| [Item 3.](#i50d87a5ec62c4d118a84439d43ce578c_115) | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i50d87a5ec62c4d118a84439d43ce578c_115)</u> | [34](#i50d87a5ec62c4d118a84439d43ce578c_115) |
| [Item 4.](#i50d87a5ec62c4d118a84439d43ce578c_118) | <u>[Controls and Procedures](#i50d87a5ec62c4d118a84439d43ce578c_118)</u> | [34](#i50d87a5ec62c4d118a84439d43ce578c_118) |
| **[PART II.](#i50d87a5ec62c4d118a84439d43ce578c_121)** | <u>[OTHER INFORMATION](#i50d87a5ec62c4d118a84439d43ce578c_121)</u> | [35](#i50d87a5ec62c4d118a84439d43ce578c_121) |
| [Item 1.](#i50d87a5ec62c4d118a84439d43ce578c_124) | <u>[Legal Proceedings](#i50d87a5ec62c4d118a84439d43ce578c_124)</u> | [35](#i50d87a5ec62c4d118a84439d43ce578c_124) |
| [Item 1A.](#i50d87a5ec62c4d118a84439d43ce578c_127) | <u>[Risk Factors](#i50d87a5ec62c4d118a84439d43ce578c_127)</u> | [35](#i50d87a5ec62c4d118a84439d43ce578c_127) |
| [Item 2.](#i50d87a5ec62c4d118a84439d43ce578c_130) | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i50d87a5ec62c4d118a84439d43ce578c_130)</u> | [36](#i50d87a5ec62c4d118a84439d43ce578c_130) |
| [Item 3.](#i50d87a5ec62c4d118a84439d43ce578c_133) | <u>[Defaults Upon Senior Securities](#i50d87a5ec62c4d118a84439d43ce578c_133)</u> | [36](#i50d87a5ec62c4d118a84439d43ce578c_133) |
| [Item 4.](#i50d87a5ec62c4d118a84439d43ce578c_136) | <u>[Mine Safety Disclosures](#i50d87a5ec62c4d118a84439d43ce578c_136)</u> | [36](#i50d87a5ec62c4d118a84439d43ce578c_136) |
| [Item 5.](#i50d87a5ec62c4d118a84439d43ce578c_139) | <u>[Other Information](#i50d87a5ec62c4d118a84439d43ce578c_139)</u> | [36](#i50d87a5ec62c4d118a84439d43ce578c_139) |
| [Item 6.](#i50d87a5ec62c4d118a84439d43ce578c_142) | <u>[Exhibits](#i50d87a5ec62c4d118a84439d43ce578c_142)</u> | [37](#i50d87a5ec62c4d118a84439d43ce578c_142) |
| <u>[Signatures](#i50d87a5ec62c4d118a84439d43ce578c_145)</u> |  | [39](#i50d87a5ec62c4d118a84439d43ce578c_145) |

---

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains "forward-looking statements" regarding The Cannabist Company Holdings Inc. and its subsidiaries (collectively referred to as "The Cannabist Company," "we," "us," "our," or the "Company"). We make forward-looking statements related to future expectations, estimates, and projections that are uncertain and often contain words such as, but not limited to, "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or other similar words or phrases. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions that are difficult to predict. Particular risks and uncertainties that could cause our actual results to be materially different from those expressed in our forward-looking statements include those listed below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of the Company's corporate restructuring activities, including, without limitation, the 2025 Debt Transaction (as defined below);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the existence of substantial doubt as to our ability to continue as a going concern, and our continuation as a going concern depends on events and circumstances that may not occur;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the review of strategic alternatives to reduce leverage and address our capital structure, which may not be successful and could create significant risks and uncertainties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the covenants contained in our debt agreements that restrict our operations and may inhibit flexibility in operating our business and pursuing strategic alternatives, and the risk that failure to comply with these covenants could have a material adverse effect on our business, financial condition and results of operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the fact that marijuana remains illegal under federal law;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the application of anti-money laundering laws and regulations to the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• legal, regulatory, or political change to the cannabis industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• access to public and private capital;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• unfavorable publicity or consumer perception of the cannabis industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expansion to the adult-use markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of laws, regulations, and guidelines;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of Section 280E of the U.S. Internal Revenue Code of 1986, as amended (the "**Internal Revenue Code**");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of state laws pertaining to the cannabis industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Company's reliance on key inputs, suppliers and skilled labor;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the difficulty of forecasting the Company's sales;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• constraints on marketing products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• potential cyber-attacks and security breaches;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• net operating loss and other tax attribute limitations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of changes in tax laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the volatility of the market price of the Company's common shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reliance on management;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• litigation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• future results and financial projections; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of global financial conditions.

The list of factors above is illustrative and by no means exhaustive. Additional information regarding these risks and other risks and uncertainties we face is contained in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2024, as well as subsequent filings. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended.

We urge readers to consider these risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**THE CANNABIST COMPANY HOLDINGS INC.**

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS

(Unaudited)

(Expressed in thousands of U.S. dollars, except share data)

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash | $17761 | $33607 |
| &nbsp;&nbsp;Accounts receivable, net of credit loss allowance of $7,907 and $6,754, respectively | 15431 | 21688 |
| &nbsp;&nbsp;Inventory | 66832 | 94516 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 14255 | 11794 |
| &nbsp;&nbsp;Notes receivable | 500 | 15614 |
| &nbsp;&nbsp;Assets held for sale | 29954 | 17778 |
| &nbsp;&nbsp;Total current assets | 144733 | 194997 |
| Property and equipment, net | 209043 | 228396 |
| Right of use assets - operating leases, net | 96827 | 124739 |
| Right of use assets - finance leases, net | 21121 | 25515 |
| Intangible assets, net | 39309 | 51249 |
| Investments | 10576 | 11880 |
| Deferred income tax assets |  | 32025 |
| Notes receivable | 2000 | 11958 |
| Other non-current assets | 12900 | 15414 |
| Total assets | $536509 | $696173 |
| **Liabilities and Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Accounts payable | $24264 | $41125 |
| &nbsp;&nbsp;Accrued expenses and other current liabilities | 24848 | 32839 |
| &nbsp;&nbsp;Income tax payable | 86973 | 87333 |
| &nbsp;&nbsp;Current portion of lease liabilities - operating leases | 6946 | 7386 |
| &nbsp;&nbsp;Current portion of lease liabilities - finance leases | 3954 | 4910 |
| &nbsp;&nbsp;Current portion of long-term debt, net | 594 | 52461 |
| &nbsp;&nbsp;Liabilities held for sale | 14550 | 2656 |
| &nbsp;&nbsp;Total current liabilities | 162129 | 228710 |
| Long-term debt, net | 298658 | 249512 |
| Long-term lease liabilities - operating leases | 97936 | 126215 |
| Long-term lease liabilities - finance leases | 34960 | 37937 |
| Derivative liabilities | 980 | 621 |
| Other long-term liabilities | 94795 | 83237 |
| Total liabilities | 689458 | 726232 |
| Commitments and contingencies |  |  |
| Stockholders' Equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock, no par value, unlimited shares authorized as of September 30, 2025 and December 31, 2024, respectively, 491,976,807 and 465,638,304 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred Stock, no par value, unlimited shares authorized as of September 30, 2025 and December 31, 2024, respectively, none issued and outstanding as of September 30, 2025 and December 31, 2024 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proportionate voting shares, no par value, unlimited shares authorized as of September 30, 2025 and December 31, 2024, respectively, 7,387,328 and 7,387,328 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;Additional paid-in-capital | 1158164 | 1156807 |
| &nbsp;&nbsp;Accumulated deficit | (1309847) | (1185501) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity attributable to The Cannabist Company Holdings Inc. | (151683) | (28694) |
| &nbsp;&nbsp;Non-controlling interest | (1266) | (1365) |
| &nbsp;&nbsp;Total equity | (152949) | (30059) |
| &nbsp;&nbsp;Total liabilities and equity | $536509 | $696173 |

---

The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**THE CANNABIST COMPANY HOLDINGS INC.**

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(Expressed in thousands of U.S. dollars, except for number of shares and per share amounts)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| Revenues, net of discounts | $79912 | $114783 | $253702 | $362584 |
| Cost of sales related to inventory production | (57001) | (70973) | (184353) | (228185) |
| Gross margin | 22911 | 43810 | 69349 | 134399 |
| &nbsp;&nbsp;&nbsp;Fixed asset impairment |  | (121) | (193) | (121) |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | (34941) | (49315) | (105182) | (142634) |
| Loss from operations | (12030) | (5626) | (36026) | (8356) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other expense: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense on leases | (693) | (850) | (2135) | (2685) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (8285) | (9744) | (32124) | (28494) |
| &nbsp;&nbsp;&nbsp;Other income (expense), net | 12687 | 36295 | (3613) | 29909 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other expense | 3709 | 25701 | (37872) | (1270) |
| Profit (loss) before provision for income taxes | (8321) | 20075 | (73898) | (9626) |
| Income tax expense | (6334) | (21838) | (50349) | (40348) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss and comprehensive loss | (14655) | (1763) | (124247) | (49974) |
| &nbsp;&nbsp;Net profit (loss) attributable to non-controlling interests | (394) | 97 | 99 | $1300 |
| Net loss attributable to shareholders | $(14261) | $(1860) | $(124346) | $(51274) |
| Weighted-average number of shares used in earnings per share - basic and diluted | 499218628 | 470552039 | 485743942 | 458988976 |
| Loss attributable to shares (basic and diluted) | $(0.03) | $— | $(0.26) | $(0.11) |

---

The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**THE CANNABIST COMPANY HOLDINGS INC.**

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

(Expressed in thousands of U.S. dollars, except for number of shares)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common<br>Shares** | **Proportionate<br>Voting Shares** | **Additional<br>Paid-in Capital** | **Accumulated<br>Deficit** | **Total The Cannabist Company Holdings Inc.<br>Shareholders' Equity** | **Non-Controlling<br>Interest** | **Total<br>Equity** |
| **Balance as of December 31, 2023** | **420265306** | **9807881** | $**1146154** | $**(1079282)** | $**66872** | $**(1520)** | $**65352** |
| Equity-based compensation (1) |  |  | 3182 |  | 3182 |  | 3182 |
| Conversion of convertible notes | 25845259 |  | 10000 |  | 10000 |  | 10000 |
| Conversion between classes of shares | 2106055 | (2106055) |  |  |  |  |  |
| Deconsolidation of subsidiary |  |  |  | (1058) | (1058) |  | (1058) |
| Net loss |  |  |  | (35073) | (35073) | 505 | (34568) |
| **Balance as of March 31, 2024** | **448216620** | **7701826** | $**1159336** | $**(1115413)** | $**43923** | $**(1015)** | $**42908** |
| Equity-based compensation (1) | 8225383 |  | (9399) |  | (9399) |  | (9399) |
| Conversion of convertible notes | 655736 |  | 200 |  | 200 |  | 200 |
| Legal settlement | 4845359 |  | 2620 |  | 2620 |  | 2620 |
| Deconsolidation of subsidiary |  |  |  | 1031 | 1031 |  | 1031 |
| Distributions |  |  |  | (333) | (333) |  | (333) |
| Net loss |  |  |  | (14341) | (14341) | 698 | (13643) |
| **Balance as of June 30, 2024** | **461943098** | **7701826** | $**1152757** | $**(1129056)** | $**23701** | $**(317)** | $**23384** |
| Equity-based compensation (1) | 1854546 |  | 2374 |  | 2374 |  | 2374 |
| Deconsolidation of subsidiary |  |  |  | 613 | 613 | (605) | 8 |
| Net profit (loss) |  |  |  | (1860) | (1860) | 97 | (1763) |
| **Balance as of September 30, 2024** | **463797644** | **7701826** | $**1155131** | $**(1130303)** | $**24828** | $**(825)** | $**24003** |
| (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amount shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. |

---

**THE CANNABIST COMPANY HOLDINGS INC.**

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY - CONTINUED

(Unaudited)

(Expressed in thousands of U.S. dollars, except for number of shares)

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common<br>Shares** | **Proportionate<br>Voting Shares** | **Additional<br>Paid-in Capital** | | **Accumulated<br>Deficit** |  | **Total The Cannabist Company Holdings Inc.<br>Shareholders' Equity** | | **Non-Controlling<br>Interest** | **Total<br>Equity** |
| **Balance as of December 31, 2024** | **465638304** | **7387328** | $**1156807** |  | $**(1185501)** |  | $**(28694)** |  | $**(1365)** | $**(30059)** |
| Equity-based compensation (1) | (93662) |  | 292 |  |  |  | 292 |  |  | 292 |
| Net loss |  |  |  |  | (32204) |  | (32204) |  | (2) | (32206) |
| **Balance as of March 31, 2025** | **465544642** | **7387328** | $**1157099** |  | $**(1217705)** |  | $**(60606)** |  | $**(1367)** | $**(61973)** |
| Equity-based compensation (1) | 6872394 |  | 525 |  |  |  | 525 |  |  | 525 |
| Conversion of convertible note | 19328305 |  |  |  |  |  |  |  |  |  |
| Distributions |  |  | (12) |  |  |  | (12) |  |  | (12) |
| Net loss |  |  |  |  | (77881) |  | (77881) |  | 495 | (77386) |
| **Balance as of June 30, 2025** | **491745341** | **7387328** | $**1157612** |  | $**(1295586)** |  | $**(137974)** |  | $**(872)** | $**(138846)** |
| Equity-based compensation (1) | 231466 |  | 552 |  |  |  | 552 |  |  | 552 |
| Conversion of convertible note |  |  |  |  |  |  |  |  |  |  |
| Distributions |  |  |  |  |  |  |  |  |  |  |
| Net loss |  |  |  |  | (14261) |  | (14261) |  | (394) | (14655) |
| **Balance as of September 30, 2025** | **491976807** | **7387328** | $**1158164** | $**—** | $**(1309847)** | $**—** | $**(151683)** | $**—** | $**(1266)** | $**(152949)** |
| (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. | (1) The amounts shown are net of any shares withheld by the Company to satisfy certain tax withholdings in connection with vesting of equity-based awards. |

---

The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**THE CANNABIST COMPANY HOLDINGS INC.**

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(Unaudited)

(expressed in thousands of U.S. dollars)

---

| | | |
|:---|:---|:---|
| | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** |
| **Cash flows from operating activities:** | | |
| &nbsp;&nbsp;Net loss | $(124247) | $(49974) |
| &nbsp;&nbsp;Adjustments to reconcile net loss to net cash (used in) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 24906 | 39314 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 1487 | (2588) |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt amortization expense | 11645 | 6794 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for credit losses | 3035 | 1689 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss / (gain) on deconsolidation of subsidiaries | 3355 | (39821) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on early extinguishment of note | 3227 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for obsolete inventory and other assets | 12340 | 5671 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative liabilities | 359 | 2329 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in investment fair value | (196) | 4195 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 32164 | (2723) |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal settlement |  | (1108) |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment on fixed assets | 193 | 121 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other |  | 836 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Changes in operating assets and liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 2380 | (5095) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 6800 | (11566) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (4028) | (4255) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 9838 | (1388) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (15494) | (543) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | (4821) | (11281) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | (360) | 38583 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | 1751 | 3450 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (35666) | (27360) |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment | (4104) | (4147) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of license | 4100 | 329 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net proceeds from sale of businesses | 13957 | 34371 |
| &nbsp;&nbsp;&nbsp;&nbsp;Note receivable settlements | 21398 | (314) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash received (paid) on deposits, net | 108 | (268) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by investing activities | 35459 | 29971 |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of debt |  | 15600 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of debt issuance costs | (12155) | (802) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of lease liabilities | (3914) | (5323) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of sellers note |  | (1119) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of debt | (100) | (13228) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of mortgage notes | (526) | (418) |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions | (12) | (333) |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes paid on equity based compensation | (120) | (1255) |
| &nbsp;&nbsp;Net cash used in financing activities | (16827) | (6878) |
| &nbsp;&nbsp;**Net decrease in cash** | (17034) | (4267) |
| &nbsp;&nbsp;Cash and restricted cash at beginning of the period | 37930 | 39337 |
| &nbsp;&nbsp;Cash and restricted cash at end of period | $20896 | $35070 |
| **Reconciliation of cash and restricted cash:** |  |  |
| Cash | $17761 | $31497 |
| Restricted cash | 3135 | 3573 |
| Cash and restricted cash, end of period | $20896 | $35070 |
| The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements. | The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements. | The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements. |

---

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**THE CANNABIST COMPANY HOLDINGS INC.**

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(Unaudited)

(expressed in thousands of U.S. dollars)

---

| | | |
|:---|:---|:---|
| | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** |
| **Supplemental disclosure of cash flow information:** | | |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |
| &nbsp;&nbsp;Operating cash flows from operating leases | $14481 | $20061 |
| &nbsp;&nbsp;Operating cash flows from finance leases | $2129 | $2679 |
| &nbsp;&nbsp;Financing cash flows from finance leases | $3914 | $5323 |
| Cash paid for interest on other obligations | $30432 | $35155 |
| Cash paid for income taxes | $7765 | $3850 |
| Lease liabilities arising from the recognition of finance right-of-use assets | $— | $6978 |
| Lease liabilities arising from the recognition of operating right-of-use assets | $— | $7 |
| **Supplemental disclosure of non-cash investing and financing activities:** |  |  |
| Non-cash fixed asset additions within accounts payable and accrued expenses | $— | $298 |
| Discount on issuance of convertible debt | $— | $(5150) |
| Reduction in debt from debt to equity conversion | $— | $(10200) |
| Increase in equity from debt to equity conversion | $— | $10200 |
| Equity issued for legal settlement | $— | $2620 |
| Exchange of notes and convertible notes for new notes and convertible notes | $269950 | $— |
| Assets held for sale | $12176 | $63551 |
| Liabilities held for sale | $11894 | $47629 |

---

The accompanying notes are an integral part of these unaudited Condensed Consolidated Interim Financial Statements.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**THE CANNABIST COMPANY HOLDINGS INC.**<br>NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS <br>FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025, and 2024<br>(Expressed in thousands of U.S. dollars, except for share and per share amounts)<br>(Unaudited)<br>

**1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OPERATIONS OF THE COMPANY**

The Cannabist Company Holdings Inc. ("the Company", "the Parent", or "The Cannabist Company"), formerly known as Columbia Care Inc., was incorporated under the laws of the Province of Ontario on August 13, 2018. The Company's principal mission is to improve lives by providing cannabis-based products to qualified patients and consumers. The Company's head office and principal address is 321 Billerica Rd., Suite 204, Chelmsford, Massachusetts 01824. The Company's registered and records office address is 666 Burrard St #1700, Vancouver, British Columbia V6C 2X8.

On April 26, 2019, the Company completed a reverse takeover ("RTO") transaction and private placement. Following the RTO, the Company's common shares were listed on Cboe Canada (formerly known as the NEO Exchange), trading under the symbol "CCHW". Effective September 19, 2023, the Company changed its name from "Columbia Care Inc." to "The Cannabist Company Holdings Inc." (the "Name Change"). In connection with the Name Change, on September 21, 2023, the Company's common shares and warrants began trading under the ticker symbols "CBST" and "CBST.WT", respectively, on Cboe Canada. On September 26, 2023, the Company's common shares began trading on the OTCQX Best Market under the ticker symbol "CBSTF," and transitioned to the OTCQB in April 2025.

**2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Basis of preparation***

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP" or "GAAP") for interim financial information and the rules and regulations of the Securities and Exchange Commission (the "SEC").

***Going Concern***

These accompanying unaudited condensed consolidated interim financial statements have been prepared on the going concern basis which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company's accounting policies.

The Company has incurred substantial net losses since its inception, including net losses of $105.1 million for the 12 months ended December 31, 2024 and $124.2 million for the nine months ended September 30, 2025. As of September 30, 2025, the Company's accumulated deficit was $1,309.8 million, and for the nine months ended September 30, 2025, the Company had negative operating cash flow of $35.7 million. As of September 30, 2025, the Company had cash and restricted cash of $20.9 million. Historically, the Company has relied on external financing as its primary source of liquidity. These conditions, together with uncertainty as to the Company's ability to generate sufficient cash flow from operations, asset divestitures or external financing sources to meet its financial obligations including, without limitation, making interest payments on its senior debt or otherwise complying with its indenture obligations, absent material divestitures, significant concessions or consents from its creditors, raise substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date of this report.

The consolidated financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. In the future, reports from our independent public accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern. In an effort to alleviate these

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

conditions and to maximize value for the Company's stakeholders, the Board of Directors (the "Board") has formed a special committee of independent directors (the "Special Committee") to review strategic alternatives. The Special Committee, with support from external financial and legal advisors, is considering a range of options, including potential asset sales, mergers, or other strategic or financial transactions. The review is being conducted in consideration of the ongoing operational and financial challenges for the Company and the industry, as well as of the continuing uncertainty as to if and when U.S. federal regulatory changes may occur that will impact the Company and the industry, including, without limitation, changes to U.S. federal taxation of the Company and the industry under Section 280(e) of the Internal Revenue Code.

If we are unable to obtain sufficient funding or otherwise complete strategic transactions on acceptable terms, or successfully negotiate with creditors with respect to waivers and/or concessions necessary to permit asset divestitures or other actions, then we will not be able to continue as a going concern and we may be forced to delay or further reduce the scope of our activities, extend payment terms with suppliers, liquidate assets where possible at a potentially lower amount than as recorded in our financial statements, further curtail planned operations or cease operations entirely and wind down our business. Any of these could materially and adversely affect our liquidity, financial condition and business prospects and, as a result, our stockholders and/or creditors may not receive full value, or may receive no value, for their investment.

The accompanying unaudited condensed consolidated interim financial statements contain all normal and recurring adjustments necessary to state fairly the consolidated financial condition, results of operations, comprehensive income, statement of shareholders' equity, and cash flows of the Company for the interim periods presented. Except as otherwise disclosed, all such adjustments consist only of those of a normal recurring nature. Operating results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results that may be expected for the current year ending December 31, 2025. The financial data presented herein should be read in conjunction with the audited consolidated financial statements and accompanying notes as of and for the years ended December 31, 2024, and 2023 included in the Annual Report on Form 10-K for the year ended December 31, 2024 (the "2024 Form 10-K").

The preparation of these unaudited condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC and the instructions to Form 10-Q.

The unaudited condensed consolidated interim financial statements are presented in United States dollars except as otherwise indicated. All references to C$, CAD$ and CDN$ are to Canadian dollars.

***Significant Accounting Judgments, Estimates and Assumptions***

The Company's significant accounting policies are described in Note 2 to the Company's 2024 Form 10-K, filed with the SEC, on March 17, 2025. There have been no material changes to the Company's significant accounting policies.

***Reclassification***

Certain reclassifications have been made to the prior period's condensed consolidated interim financial statements and notes to conform to the current year presentation. These reclassifications do not impact the gross margin, profit (loss) from operations, loss before provision for income taxes, and net loss and comprehensive loss presented on the condensed consolidated interim statements of operations and comprehensive loss.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

***Revenue***

The Company's revenues are disaggregated as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| Dispensary | $65313 | $95223 | $204896 | $308554 |
| Cultivation and wholesale | 14599 | 19560 | 48806 | 54030 |
|  | $79912 | $114783 | $253702 | $362584 |

---

During the three and nine months ended September 30, 2025, the Company netted discounts of $19,960 and $65,212, respectively, against the revenues. During the three and nine months ended September 30, 2024, the Company netted discounts of $31,482 and $105,366, respectively, against the revenues. Discounts are provided by the Company during promotional days or weekends. Discounts are also provided to employees, seniors, and other categories of customers and may include price reductions and coupons.

**3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INVENTORY**

Details of the Company's inventory are shown in the table below:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Accessories and supplies | $782 | $1064 |
| Work-in-process - cannabis in cures and final vault | 42545 | 66933 |
| Finished goods - dried cannabis, concentrate and edible products | 23505 | 26519 |
| **Total inventory** | $66832 | $94516 |

---

The inventory values are net of inventory write-downs as a result of obsolescence or unmarketability charged to cost of sales. As a result of certain restructuring efforts, there were write-downs of $2,804 and $13,375 during the three and nine months ended September 30, 2025, respectively. As a result of certain restructuring efforts, there were write-downs of $30 and $5,617 during the three and nine months ended September 30, 2024.

Inventory is stated net of provision of $2,167 and $5,478 as of September 30, 2025 and December 31, 2024, respectively.

**4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CURRENT AND LONG-TERM DEBT**

Current and long-term obligations, net, are shown in the table below:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| 2026 Notes | $— | $185000 |
| 2027 Convertible Notes |  | 25450 |
| 2025 Convertible Notes |  | 59500 |
| 2028 Notes | 250750 |  |
| 2028 Convertible Notes | 19200 |  |
| Mortgage Note | 40615 | 42923 |
|  | 310565 | 312873 |
| Unamortized debt discount | (11025) | (6156) |
| Unamortized deferred financing costs | (288) | (4744) |
| **Total debt, net** | 299252 | 301973 |
| Less current portion, net\* | (594) | (52461) |
| **Long-term portion** | $298658 | $249512 |

---

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

\*The current portion of the debt includes scheduled payments on the mortgage notes, convertible notes, and notes, net of corresponding portions of the unamortized debt discount and unamortized deferred financing costs.

The Company was in compliance with all financial covenants and was not in default of any provisions under any of its debt arrangements as of September 30, 2025.

*2026 Notes*

On February 3, 2022, the Company closed a private placement (the "February 2022 Private Placement") of $185,000 aggregate principal amount of 9.50% senior-secured first-lien notes due 2026 (the "2026 Notes") and received aggregate gross proceeds of $153,250. The 2026 Notes were senior secured obligations of the Company and were issued at 100.0% of face value. The 2026 Notes accrued interest in arrears which was payable semi-annually and were scheduled to mature on February 3, 2026, unless earlier redeemed or repurchased. The Company may redeem the 2026 Notes at par, in whole or in part, on or after February 3, 2024, as more particularly described in the fourth supplemental trust indenture governing the 2026 Notes. In connection with the offering of the 2026 Notes, the Company exchanged $31,750 of the Company's existing 13.0% senior secured first-lien notes (the "13.0% Term Debt"), pursuant to private agreements in accordance with the trust indenture, for an equivalent amount of 2026 Notes plus accrued but unpaid interest and any negotiated premium thereon.

The premium and paid interest were paid out of funds raised from the February 2022 Private Placement. The total unamortized debt premium and debt issuance costs of $2,153, related to the modified portion of the 13.0% Term Debt, was being amortized over the term of the 2026 Notes using the effective interest method. The Company incurred $7,189 in creditor fees in connection with the modified 13.0% Term Debt and 2026 Notes and $301 in third-party legal fees related to 2026 Notes, which were capitalized and were being amortized over the term of the 2026 Notes using the effective interest rate method.

On May 29, 2025, the 2026 Notes were exchanged for the 2028 Notes, see 2025 Debt Transactions (the 2028 Notes and the 2028 Convertible Notes). At the time of the exchange, the remaining unamortized debt premium, debt issuance costs, collector fees, and third party legal fees of $2,216 were written off.

*2027 Convertible Notes*

On March 19, 2024, the Company closed a private placement (the "March 2024 Private Placement") of $25,750 aggregate principal amount of 9.0% senior-secured first-lien notes due 2027 (the "2027 Convertible Notes") and received aggregate gross proceeds of $15,600. The 2027 Convertible Notes were senior secured obligations of the Company and were issued at 80.0% of face value. The 2027 Convertible Notes accrued interest in arrears which was payable semi-annually and were scheduled to mature on March 19, 2027. In connection with the offering of the 2027 Convertible Notes, the Company exchanged $5,000 of the Company's existing 6.0% 2025 Convertible Notes. Through September 30, 2025, 983,604 shares were issued to convert $300 principal.

The principal amount of the 2027 Convertible Notes and the conversion price were denominated in U.S. dollars. As the debt was issued out of the Company's Canadian Holding company, but the functional currency of the Company is US Dollars, the amount of the liability to be settled depends on the applicable foreign exchange rate on the date of settlement. The 2027 Convertible Notes therefore represented an obligation to issue a fixed number of shares for a variable amount of liability. Due to this conversion feature within the 2027 Convertible Notes, the Company was unable to obtain an exception from derivative accounting. Accordingly, this conversion feature was accounted for as an embedded derivative liability and measured at fair value of $2,632 on the date of issuance of debt with a corresponding debt discount and debt issuance costs of $5,952, reflected as a reduction to the carrying value of the 2027 Convertible Notes. The Company fair valued the derivative liability at each balance sheet date. Changes in fair value of the embedded derivative were recognized in the condensed consolidated interim statements of operations and comprehensive loss. The debt discount and debt issuance costs were being amortized over the term of the 2027 Convertible Notes.

On May 29, 2025, the 2027 Convertible Notes were exchanged for the 2028 Notes, see 2025 Debt Transactions (the 2028 Notes and the 2028 Convertible Notes). At the time of the exchange, the remaining unamortized debt discount and debt issuance costs of $3,759 were written off.

*2025 Convertible Notes*

On June 29, 2021, the Company completed an offering of 6.0% Secured Convertible Notes Due 2025 ("2025 Convertible Notes") for an aggregate principal amount of $74.5 million. The 2025 Convertible Notes were

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

senior secured obligations of the Company and accrued interest payable semiannually in arrears and were scheduled to mature on June 29, 2025, unless earlier converted, redeemed, or repurchased. The 2025 Convertible Notes shall be convertible, at the option of the holder, from the date of issuance until the date that is 10 days prior to their maturity date into Common Shares of the Company at a conversion price equal to $6.49 payable on the business day prior to the date of conversion, adjusted downwards for any cash dividends paid to holders of Common Shares and other customary adjustments. The Company may redeem the 2025 Convertible Notes at par, in whole or in part, on or after June 29, 2023, if the volume weighted average price of the Common Shares trading on the Canadian Stock Exchange or Cboe Canada for 15 of the 30 trading days immediately preceding the day on which the Company exercises its redemption right, exceeds 120.0% of the conversion price of the 2025 Convertible Notes at a Redemption Price equal to 100.0% of the principal amount of the 2025 Convertible Notes redeemed, plus accrued but unpaid interest, if any, up to but excluding the Redemption Date.

The 2025 Convertible Notes required interest-only payments until June 29, 2025, at a rate of 6.0% per annum, payable semi-annually in June and December and commencing in December 2021. The 2025 Convertible Notes were schedule to mature on June 29, 2025. The Company incurred financing costs of $3,190 in connection with the 2025 Convertible Notes. The principal amount of the 2025 Convertible Notes and the conversion price were denominated in U.S. dollars. As the debt was issued out of the Company's Canadian Holding company, but the functional currency of the Company is US Dollars, the amount of the liability to be settled depends on the applicable foreign exchange rate on the date of settlement. The 2025 Convertible Notes therefore represent an obligation to issue a fixed number of shares for a variable amount of liability. Due to this conversion feature within the 2025 Convertible Notes, the Company was unable to obtain an exception from derivative accounting. Accordingly, this conversion feature was accounted for as an embedded derivative liability and measured at fair value of $15,099 on the date of issuance of debt with a corresponding debt discount, reflected as a reduction to the carrying value of the 2025 Convertible Notes. The Company fair valued the derivative liability at each balance sheet date. Changes in fair value of the embedded derivative were recognized in the condensed consolidated interim statements of operations and comprehensive loss. The debt discount was amortized over the term of the 2025 Convertible Notes.

On May 29, 2025, the 2025 Convertible Notes were exchanged for the 2028 Notes, see 2025 Debt Transactions (the 2028 Notes and the 2028 Convertible Notes). At the time of the exchange, the remaining unamortized finance costs of $973, were written off.

*January 2024 Debt Exchange*

On January 22, 2024, the Company entered into an exchange agreement, as amended on June 30, 2024 and September 30, 2024 (the "Exchange Agreement"), with certain holders of the Company's 6.0% senior secured 2025 Convertible Notes (the "Holders"), pursuant to which the Company agreed to the repurchase of up to $25 million principal amount of the 2025 Convertible Notes in exchange for Common Shares (the "January 2024 Debt Exchange").

Pursuant to the terms of the Exchange Agreement, the Holders shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• by January 31, 2024, transfer $5 million principal amount of 2025 Convertible Notes in consideration of Common Shares issued at a price per Common Share equal to the greater of C$0.41 per Common Share and the 12.5% discount to the 5 days volume weighted average price of the Common Shares on Cboe prior to receipt of a Transfer notice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• provided that the five-day volume weighted average price of the Common Shares on the Exchange is greater than C$0.47 as of the close of trading at 4:01pm on January 31, 2024, transfer $5 million principal amount of 2025 Convertible Notes in consideration of Common Shares issued at the Initial Exchange Price on or prior to February 29, 2024; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• provided that the February Exchange is completed and the daily volume weighted average price of the Common Shares on Cboe is greater than C$0.87 for 5 consecutive trading days, provided that, the trading volume of the Common Shares on Cboe was equal to or greater than 600,000 Common Shares on the applicable trading dates, from the period commencing on January 1, 2024 and ending on September 30, 2025, (which date the parties extended to December 31, 2024), transfer in three separate equal tranches, an aggregate of $15 million principal amount of 2025 Convertible Notes in consideration of Common Shares issued at a price per Common Share equal to the greater of C$0.57 per Common Share and the 12.5%

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

discount to the 5 days volume weighted average price of the Common Shares on Cboe prior to receipt of a Transfer notice, in each case, subject to adjustment in certain instances, on or prior to December 31, 2024.

Through December 31, 2024, $10 million of the potential $25 million exchange had been completed. The term of the Exchange Agreement expired as of January 31, 2025.

*2025 Debt Transaction (the 2028 Notes and the 2028 Convertible Notes)* 

On February 27, 2025, the Company entered into a support agreement (the "Support Agreement") with certain holders (the "Supporting Noteholders") of the aggregate principal amount of issued Senior Notes (as defined below) regarding the exchange of their Senior Notes for new notes having a later maturity date and additional covenants (the "2025 Debt Transaction"). The Senior Notes consist of: (i) the 2025 Convertible Notes; (ii) the 2026 Notes; and (iii) the 2027 Notes (together with the 2025 Convertible Notes and the 2026 Notes, the "Senior Notes"). Under the terms of the 2025 Debt Transaction, among other provisions, the holders of the 2025 Convertible Notes and the 2026 Notes exchanged their Senior Notes for an equal principal amount of 9.25% Senior Secured Notes due December 31, 2028 (subject to two six-month extension options available to the Company upon payment of a 0.5% fee, payable in cash) (the "2028 Notes") and the holders of the 2027 Notes received either (i) an equal principal amount of the 2028 Notes or (ii) if elected, an equal principal amount of newly issued 9.0% convertible notes, which have the same conversion price as the existing 2027 Notes but will the same extended maturity date as the 2028 Notes (the "2028 Convertible Notes", and together with the 2028 Notes, the "New Notes").

The 2028 Notes and 2028 Convertible Notes require interest-only payments until December 31, 2028, payable semi-annually in June and December and commencing in December 2025 until maturity. The Company incurred financing costs of $12,155 in connection with the 2025 Debt Transaction. The principal amount of the 2028 Convertible Notes and the conversion price are denominated in U.S. dollars. As the debt was issued out of the Company's Canadian Holding company, but the functional currency of the Company is US Dollars, the amount of the liability to be settled depends on the applicable foreign exchange rate on the date of settlement. The 2028 Convertible Notes therefore represent an obligation to issue a fixed number of shares for a variable amount of liability. Due to this conversion feature within the 2028 Convertible Notes, the Company is unable to obtain an exception from derivative accounting. Accordingly, this conversion feature was accounted for as an embedded derivative liability and measured at fair value of $230 on the date of issuance of debt with a corresponding debt discount, reflected as a reduction to the carrying value of the 2028 Convertible Notes. The Company fair values the derivative liability at each balance sheet date. Changes in fair value of the embedded derivative are recognized in the condensed consolidated interim statements of operations and comprehensive loss. The debt financing costs are amortized over the term of the 2028 Notes and 2028 Convertible Notes.

In addition, as part of the 2025 Debt Transaction, the Company issued 118,209,105 warrants to the Company shareholders on a pro rata basis, see Note 10 Warrants.

The 2028 Notes and 2028 Convertible Notes are secured by a first-priority security interest in all present and after-acquired personal property of the Company, including a pledge of the Equity Interests owned by the Issuer and each Guarantor; and a collateral assignment of leases in respect of certain leasehold property and all of the Company's interests therein as defined in the Amended and Restated Trust Indenture.

The Company completed its 2025 Debt Transaction effective May 29, 2025 following receipt of court approval.

*Mortgages*

In December 2021, the Company entered into a term loan and security agreement with a bank. The agreement provides for a $20,000 mortgage on real property in New York and carries interest at a variable rate per annum equal to the Wall Street Prime Rate ("Index") plus 2.25%. The debt is repayable in 59 monthly installments and a final balloon payment due on January 1, 2027, which is estimated at $17,907 as of September 30, 2025. In connection with this mortgage, the Company incurred financing costs of $655.

In June 2022, the Company entered into a term loan and security agreement with a bank. The agreement provides for a $16,500 mortgage on real property in New Jersey and carries interest at a variable rate per annum equal to the Index plus 2.25%. The debt is repayable in 59 monthly installments and a final balloon payment due on July 15, 2027, which is estimated at $15,536 as of September 30, 2025. In connection with this mortgage, the Company incurred financing costs of $209.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

On August 10, 2023, the Company entered into two term loans and security agreements with a bank as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The first agreement provides for a $6,250 mortgage on real property in Maryland and carries interest at a variable rate per annum equal to the Index plus 2.25%. The debt is repayable in 59 monthly installments and a final balloon payment due on September 1, 2028, which is estimated at $5,892 as of September 30, 2025. In connection with this mortgage, the Company incurred financing costs of $195 and netted $2,903 after the repayment of a prior outstanding mortgage on the property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The second agreement provides for a $1,800 mortgage on real property in Delaware and carries interest at a variable rate per annum equal to the Index plus 2.25%. The debt was repayable in 59 monthly installments and matures in August 2028. In connection with this mortgage, the Company incurred financing costs of $77 and netted $1,723. The mortgage was paid in full on January 15, 2025 with the sale of the property.

Total interest and amortization expense on the Company's debt obligations during the three and nine months ended September 30, 2025 and 2024 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| Interest expense on debt | $7380 | $7595 | $21361 | $22308 |
| Amortization of debt discount |  | 1509 | 6156 | 4014 |
| Amortization of debt issuance costs | 967 | 978 | 5489 | 2780 |
| Other interest expense (income), net | (62) | (338) | (882) | (608) |
| **Total interest expense, net** | $8285 | $9744 | $32124 | $28494 |

---

The weighted average interest rate on the Company's indebtedness was 9.23%.

**5. PROPERTY AND EQUIPMENT**

Details of the Company's property and equipment and related depreciation expense are summarized in the tables below:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Land and buildings | $109052 | $115277 |
| Furniture and fixtures | 4931 | 6804 |
| Equipment | 30966 | 34367 |
| Computers and software | 2019 | 2363 |
| Leasehold improvements | 151460 | 155529 |
| Construction in process | 3155 | 6565 |
| &nbsp;&nbsp;&nbsp;**Total property and equipment, gross** | 301583 | 320905 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: accumulated depreciation | (92540) | (92509) |
| &nbsp;&nbsp;&nbsp;**Total property and equipment, net** | $209043 | $228396 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| Total depreciation expense for three and nine months ended | $4481 | $8314 | $13692 | $23589 |
| Included in: |  |  |  |  |
| Costs of sales related to inventory production | $2897 | $5216 | $8904 | $14782 |
| Selling, general and administrative expenses | $1584 | $3098 | $4788 | $8807 |

---

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**6. PREPAID EXPENSES AND OTHER CURRENT ASSETS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Details of the Company's prepaid expenses and other current assets are summarized in the table below:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Prepaid expenses | $9027 | $8719 |
| Short term deposits | 1150 | 914 |
| Other current assets | 4074 | 1932 |
| Excise and sales tax receivable | 4 | 229 |
| **Prepaid expenses and other current assets** | $14255 | $11794 |

---

**7. OTHER NON-CURRENT ASSETS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Details of the Company's other non-current assets are summarized in the table below:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Long term deposits | $7376 | $8604 |
| Long term tax receivable | 1614 | 1712 |
| Investment in affiliates | 775 | 775 |
| Restricted cash | 3135 | 4323 |
| **Other non-current assets** | $12900 | $15414 |

---

**8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Details of the Company's accrued expenses and other current liabilities are summarized in the table below:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Taxes - property and other | $1159 | $4912 |
| Other accrued expenses | 13409 | 13477 |
| Payroll liabilities | 8938 | 10709 |
| Other current liabilities | 1342 | 3741 |
| **Accrued expenses and other current liabilities** | $24848 | $32839 |

---

**9. SHAREHOLDERS' EQUITY**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company had the following activity during the three and nine months ended September 30, 2025:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cancelled 93,662 of Restricted Stock Units (RSUs) during the nine months ended September 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Issued 6,872,394 common shares upon vesting of Restricted Stock Units (RSUs).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Issued 19,328,305 common shares in connection with the 2028 Convertible Notes.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**10. WARRANTS**

As of September 30, 2025 and December 31, 2024, outstanding warrants to purchase Common Shares consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **September 30, 2025** | **September 30, 2025** | **December 31, 2024** | **December 31, 2024** |
|<br>**Expiration** | **Number of Shares<br>Issued and Exercisable** | **Exercise Price**<br>**(Canadian Dollars)** | **Number of Shares<br>Issued and Exercisable** | **Exercise Price**<br>**(Canadian Dollars)** |
| September 21, 2026 | 11122105 | $1.96 | 11122105 | $1.96 |
| October 1, 2025 | 648783 | 8.12 | 648783 | 8.12 |
| May 29, 2027 | 118246947 | $0.14 |  | $— |
|  | 130017835 | $0.34 | 11770888 | $2.30 |

---

Warrant activity for the nine months ended September 30, 2025 and 2024 are summarized in the table below:

---

| | | |
|:---|:---|:---|
| | **Number of**<br>**Warrants**  | **Weighted average<br>exercise price<br>(Canadian Dollars)** |
| **Balance as of December 31, 2023** | 17165833 | $4.83 |
| Issued |  |  |
| Expired | (5394945) | 10.35 |
| **Balance as of September 30, 2024** | 11770888 | $2.30 |
| **Balance as of December 31, 2024** | 11770888 | $2.30 |
| Issued | 118246947 | 0.14 |
| Expired |  |  |
| **Balance as of September 30, 2025** | 130017835 | $0.34 |

---

**11. LOSS PER SHARE**

Basic and diluted net loss per share attributable to the Company was calculated as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| Numerator: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(14655) | $(1763) | $(124247) | $(49974) |
| &nbsp;&nbsp;&nbsp;Less: net profit attributable to non-controlling interests | (394) | 97 | 99 | 1300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss attributable to shareholders | $(14261) | $(1860) | $(124346) | $(51274) |
| Denominator: |  |  |  |  |
| Weighted average shares outstanding - basic and diluted | 499218628 | 470552039 | 485743942 | 458988976 |
| Loss per share - basic and diluted | $(0.03) | $— | $(0.26) | $(0.11) |

---

Certain share-based equity awards were excluded from the computation of dilutive loss per share because inclusion of these awards would have had an anti-dilutive effect.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**12. COMMITMENTS AND CONTINGENCIES** 

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited.

Additionally, the Company may be contingently liable with respect to other claims incidental to the ordinary course of its operations. Except as described below, in the opinion of management, and based on management's consultation with legal counsel, the ultimate outcome of such other matters will not have a materially adverse effect on the Company. Accordingly, no provision has been made in these consolidated financial statements for losses, if any, which might result from the ultimate disposition of these matters should they arise.

Murchinson Ltd., an investment manager of holders of 2025 Convertible Notes and 2027 Convertible Notes, subsequently exchanged for 2028 Notes (the "Applicant"), filed an application in the Ontario Superior Court of Justice (Commercial List) (the "Court") on March 27, 2025, opposing the 2025 Debt Transaction and claiming the transaction was oppressive to the Applicant. The application filed by the Applicant also claimed breach of contract and civil conspiracy. The Applicant sought from the court, among other forms of relief, that the 2025 Debt Transaction be declared unlawful under the terms of the Canadian Business Corporations Act, an award of unspecified damages, and recovery of costs. By order dated May 21, 2025, the Court ruled in favor of the Company and the 2025 Debt Transaction was subsequently closed. Murchinson Ltd. has filed an appeal to the Court of Appeal for Toronto that is currently pending with a hearing scheduled in February 2026.

**13. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS**

*<u>Fair Value Measurements</u>* 

The following table presents the Company's financial instruments that are measured at fair value on a recurring basis:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **September 30, 2025** | | | | |
| Investment securities | $10576 | $— | $— | $10576 |
| Total assets | $10576 | $— | $— | $10576 |
| Derivative liabilities | $— | $— | $(980) | $(980) |
| Total liabilities | $— | $— | $(980) | $(980) |
| **December 31, 2024** |  |  |  |  |
| Investment securities | $11880 | $— | $— | $11880 |
| Total assets | $11880 | $— | $— | $11880 |
| Derivative liability | $— | $— | $(621) | $(621) |
| Total liabilities | $— | $— | $(621) | $(621) |

---

During the period included in these financial statements, there were no transfers of amounts between levels.

Level 1 investment securities are stated at observable inputs such as quoted prices in active markets.

The following table summarizes the valuation techniques and key inputs used in the fair value measurement of Level 3 financial instruments:

---

| | | | |
|:---|:---|:---|:---|
| **Financial asset/financial<br>liability** | **Valuation techniques** | **Significant unobservable<br>inputs** | **Relationship of unobservable<br>inputs to fair value** |
| Derivative liability | Market approach | Conversion period | Increase or decrease in conversion period will result in an increase or decrease in fair value |

---

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

There has been no change in the valuation methodology for the nine months ended September 30, 2025. The carrying amounts of cash and restricted cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities, the current portion of long-term debt, and lease liabilities as of September 30, 2025 and December 31, 2024 approximate their fair values because of the short-term nature of these items and are not included in the table above. The Company's other long-term liabilities and long-term debt approximate fair value due to the market rate of interest used on initial recognition.

In addition to the disclosures for assets and liabilities required to be measured at fair value at the balance sheet date, companies are required to disclose the estimated fair values of all financial instruments, even if they are not presented at their fair value on the consolidated balance sheet. The fair values of financial instruments are estimates based upon market conditions and perceived risks as of September 30, 2025 and December 31, 2024. These estimates require management's judgment and may not be indicative of the future fair values of the assets and liabilities.

**14. INTANGIBLE ASSETS** 

Intangible assets consist of the following:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Licenses | $99162 | $109973 |
| Trademarks | 23075 | 23810 |
| Customer relationships | 15264 | 15263 |
| Total intangible assets | 137501 | 149046 |
| Less: accumulated amortization | (98192) | (97797) |
| Total intangible assets, net | $39309 | $51249 |

---

Amortization expense for the three and nine months ended September 30, 2025 and 2024 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| Amortization expense | $2178 | $2759 | $6783 | $8924 |

---

**15. SELLING, GENERAL AND ADMINISTRATIVE EXPENSES**

Selling, general and administrative expenses are summarized in the table below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| Salaries and benefits | $15550 | $22705 | $45989 | $61841 |
| Professional fees | 1845 | 3489 | 5659 | 8437 |
| Depreciation and amortization | 4448 | 6013 | 13622 | 19778 |
| Operating facilities costs | 8111 | 10331 | 23253 | 32001 |
| Operating office and general expenses | 3649 | 5132 | 12439 | 15839 |
| Advertising and promotion | 1116 | 502 | 3470 | 2309 |
| Other fees and expenses | 222 | 1143 | 750 | 2429 |
| **Total selling, general and administrative expenses** | $34941 | $49315 | $105182 | $142634 |

---

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**16. OTHER (INCOME) EXPENSE, NET**

Other (income) expense, net is summarized in the table below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| Change in fair value of the derivative liability | $— | $— | $359 | $2329 |
| Change in fair value of investments | (6716) | 4195 | (196) | 4195 |
| Restructuring expense | 1319 | 1207 | 2423 | 5749 |
| Other (income) /expense, net | (415) | (1191) | (2245) | (2185) |
| Adjustment for held-for-sale | (2867) | 16420 | 1 | 16420 |
| (Gain) / loss on disposal | (3936) | (56865) | 3391 | (56241) |
| Rental income | (72) | (61) | (120) | (176) |
| **Total other (income) / expense, net** | $(12687) | $(36295) | $3613 | $(29909) |

---

During the nine months ended September 30, 2025 and 2024, the Company recorded $2,423 and $5,749 in restructuring expense, respectively. As of September 30, 2025 and 2024, the balance outstanding on the Company's restructuring reserve was $820 and $4,731 respectively.

The net gain on disposal for the 3 months ended September 30, 2025 arose primarily from the divestiture of the Pennsylvania stores and Balboa, California. The net loss on disposal for the nine months ended September 30, 2025 arose primarily from the impact of other divestitures in California as delineated in Note 17 below. Gains and losses are stated net of any gains and losses attributable to minority investors.

&nbsp;&nbsp;&nbsp;&nbsp;**17. DIVESTITURE**

*Utah Business Divestiture* 

On October 6, 2023, the Company entered into a definitive agreement, subject to closing conditions, to dispose of its Utah operations (the "Utah Business") which are considered non-core and comprised of one dispensary and one cultivation facility. The Utah Business was divested for gross proceeds of approximately $6.5 million, with approximately $3.9 million due on closing of the transaction, and a $2.6 million Seller note payable to the Company not later than July 2025. The sale of the Utah assets was completed on March 7, 2024 and the Company received an early settlement of the Seller note on April 1, 2025 in the amount of $2.0 million.

*Arizona Divestiture*

On July 29, 2024, the Company entered into definitive agreements, subject to closing conditions, to dispose of its Arizona operations (the "Arizona Business") which are comprised of two dispensaries and one cultivation / manufacturing facility. The Arizona Business was divested for gross proceeds of $15 million, with approximately all $15 million which was received on signing of the definitive agreement.

*Eastern Virginia Divestiture*

On July 29, 2024, the Company entered into a definitive agreement, subject to closing conditions, to dispose of a portion of its Virginia operations (the "East Virginia Business") which are comprised of six dispensaries and one cultivation / manufacturing facility. The East Virginia Business was divested for gross proceeds of $90 million, consisting of approximately $20 million in cash, $40 million of equity in the Buyer, Verano Holdings Corp., due on closing of the transaction, and a $30 million seller note payable to the Company over a 14 month period.

In May 2025, the Company reached an agreement on the early settlement of the balance on this seller note receivable, with a $10.0 million one-time payment made as full and early settlement of the note. Accordingly, there is a $0 balance receivable on the note subsequent to the one-time payment. The related proceeds from this early settlement are included within Investing Activities in the Statement of Cash Flows.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

*Florida Business Divestiture*

On November 7, 2024, the Company sold the majority of its Florida operations (the "Florida Business") through the sale of fourteen dispensaries and two cultivation / manufacturing facilities for gross proceeds of $5 million, consisting of approximately $3 million in cash and $2 million of promissory note. Following the sale of the Florida Business, the Company had one license and one cultivation facility in the state, neither of which remained in active operation. On April 17, 2025, the Company sold the license for $5 million in cash of which $4.1 million has been paid to date and $900 thousand remains receivable as of September 30, 2025 and is recorded in prepaid expenses and other current assets on the condensed consolidated interim balance sheet. In connection to the sale of the license, the Company has the potential for an additional $2.5 million contingent payment in the event of an adult use program in the state.

*Milford, Delaware Divestiture*

On January 15, 2025, the Company sold its Milford II cultivation property, which had not yet been developed and was a non-operating asset. Gross proceeds from the sale were $3.37 million, approximately $1.8 million of which was used to fully settle the outstanding mortgage on the property.

*North Hollywood, California Divestiture*

On March 18, 2025, the Company entered into a definitive agreement, subject to closing conditions, to dispose of its North Hollywood dispensary (the "NoHo store"). The NoHo store was divested for gross proceeds of approximately $1.375 million, with approximately $715 thousand paid up-front and the balance received in July 2025. Nothing remains receivable as of September 30, 2025.

*DeSoto, California Divestiture*

On April 3, 2025, the Company entered into a definitive agreement, subject to closing conditions, to dispose of its DeSoto, San Diego, dispensary (the "DeSoto store"). The DeSoto store was divested for gross proceeds of approximately $1 million, with approximately $500 thousand paid up-front and the balance due on completion of closing conditions.

*THC, California Divestiture*

On April 15, 2025, the Company entered into a definitive agreement, subject to closing conditions, to dispose of its THC, San Diego, dispensary (the "THC store"). The THC store was divested for gross proceeds of approximately $1 million, with approximately $500 thousand paid up-front and the balance due on completion of closing conditions.

*Balboa, California divestiture*

On July 1, 2025, the Company entered into a definitive agreement, subject to closing conditions, to dispose of its Balboa, CA facility ("Balboa"). The Balboa facility was divested for gross proceeds of approximately $0.7 million, with approximately $0.4 million of gross proceeds paid up-front and the balance due on the completion of certain closing conditions. The balance of $0.3 million remains receivable as of September 30, 2025 and is recorded in prepaid expenses and other current assets on the condensed consolidated interim balance sheet.

*Pennsylvania Stores divestiture*

On August 4, 2025, the Company entered into a definitive agreement to dispose of its three Pennsylvania retail stores (the "Pennsylvania stores"). The Pennsylvania stores were divested for gross proceeds of approximately $10 million, $1 million of which was placed into escrow and subject to release over a period up to 18 months from the Closing date and is recorded in prepaid expenses and other current assets on the condensed consolidated interim balance sheet.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

The table below summarizes the operating results of the disposed of business for the three and nine months ended September 30, 2025, and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| **Arizona** | | | | |
| Revenue | $— | $2179 | $— | $11857 |
| Expense | $— | $1985 | $— | $10747 |
| **District of Columbia** |  |  |  |  |
| Revenue | $— | $301 | $— | $991 |
| Expense | $— | $518 | $— | $1597 |
| **Eastern Virginia** |  |  |  |  |
| Revenue | $— | $6979 | $— | $29809 |
| Expense | $— | $3665 | $— | $17427 |
| **Florida** |  |  |  |  |
| Revenue | $— | $4864 | $— | $17772 |
| Expense | $— | $10731 | $— | $36968 |
| **Utah** |  |  |  |  |
| Revenue | $— | $— | $— | $943 |
| Expense | $— | $— | $— | $822 |
| **California** |  |  |  |  |
| Revenue | $— | $— | $5074 | $— |
| Expense | $231 | $— | $5998 | $— |
| **Pennsylvania** |  |  |  |  |
| Revenue | $1662 | $— | $7946 | $— |
| Expense | $1551 | $— | $9632 | $— |
| **Total** |  |  |  |  |
| Revenue | $1662 | $14323 | $13020 | $61372 |
| Expense | $1782 | $16899 | $15630 | $67561 |

---

&nbsp;&nbsp;&nbsp;&nbsp;**18. NET ASSETS HELD FOR SALE**

During 2023, the Company committed to a plan to sell its Utah operations. Accordingly, certain of the assets and liabilities held by the Company's Utah subsidiary were presented as a disposal group held for sale on the consolidated balance sheet as of December 31, 2023. The sale of the Utah assets was completed on March 7, 2024.

On November 7, 2024, the Company sold its Florida Business through the sale of fourteen dispensaries and two cultivation / manufacturing facilities for gross proceeds of $5 million, consisting of approximately $3 million in cash and $2 million of promissory note. Following the sale of the Florida Business, the Company had one license and one leasehold interest in a cultivation facility in the state, neither of which remained in active operation. On April 17, 2025, the Company sold the license for $5 million in cash, with the potential for an additional $2.5 million contingent payment in the event of an adult use program in the state. On September 22, 2025, the Company entered into a definitive agreement, subject to closing conditions, to sell the leasehold interest and equipment in the cultivation facility for gross proceeds of $11 million with the potential for an additional $1 million contingent payment in the event of an adult use program in the state.

In early 2025, the Company committed to a plan to sell its Illinois operations (the "Illinois Business") which are comprised of two dispensaries and one cultivation / manufacturing facility.

In early 2025, the Company also committed to a plan to sell its remaining California operations (the "remaining California Business") which is comprised of three dispensaries and one cultivation / manufacturing facility. During the six months ended June 30, 2025, the Company disposed of two of the three dispensaries, see Note 17 Divestitures

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

(DeSoto and THC). In July 2025, the cultivation / manufacturing facility was divested and as of September 30, 2025, one dispensary remains to be sold.

The planned disposals as of September 30, 2025 did not represent a strategic shift of the Company that had or will have a major effect on the Company's operations and financial results. Accordingly, the operations were not segregated and were presented as continuing operations in the condensed consolidated interim statements of operations and comprehensive loss as of September 30, 2025 and December 31, 2024. The disposal group was stated at fair value less costs to sell and comprised the following assets and liabilities:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Cash | $— | $239 |
| Accounts receivable | 724 | 34 |
| Inventory | 4465 | 364 |
| Prepaid expenses and other current assets | 630 | 381 |
| Property, plant and equipment | 10394 | 9516 |
| Right-of-use assets | 12858 | 2364 |
| Right of use assets - finance leases, net | 96 | 102 |
| Intangible assets, net | 787 | 4778 |
| **Assets held for sale** | $29954 | $17778 |
| Accounts payable and other liabilities | $(987) | $(104) |
| Lease liabilities | (13563) | (2552) |
| **Liabilities held for sale** | $(14550) | $(2656) |

---

The non-recurring fair value measurement for the disposal group has been categorized as a Level 3 fair value utilizing Level 3 inputs and using a market approach, based on available data for transactions in the region and discussions with potential acquirers.

**19. SUBSEQUENT EVENT**

**<u>Sale of Inactive Real Estate Interests</u>**: On October 3, 2025, the Company completed the sale of a property in New Jersey for gross proceeds of $2.55 million pursuant to a regulatory taking initiated by the state. The property had originally been intended for a dispensary, which never opened, and was ultimately opened at a different location. On November 10, 2025, the Company completed the sale of its leasehold interest and equipment in a cultivation facility in Florida for gross proceeds of $11 million with the potential for an additional $1 million contingent payment in the event of an adult use program in the state, subject to certain conditions. The cultivation facility had been inactive since the second half of 2024 following the Company's announced exit from the Florida market. The Company has no remaining assets in Florida.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

*This management's discussion and analysis ("MD&A") of the financial condition and results of operations of The Cannabist Company Holdings Inc. ("The Cannabist Company", the "Company", "us", "our" or "we") is supplemental to, and should be read in conjunction with, The Cannabist Company's unaudited condensed consolidated interim financial statements and the accompanying notes for the three and nine months ended September 30, 2025 and 2024. Except for historical information, the discussion in this section contains forward-looking statements that involve risks and uncertainties. Future results could differ materially from those discussed below for many reasons, including the risks described in "Disclosure Regarding Forward-Looking Statements," "Item 1A-Risk Factors" and elsewhere in the Company's 2024 Form 10-K filed with the SEC on March 17, 2025 and subsequent securities filings.*

*The Cannabist Company's financial statements are prepared in accordance with generally accepted accounting principles in the United States of America ("US GAAP"). Financial information presented in this MD&A is presented in thousands of United States dollars ("$" or "US$"), unless otherwise indicated.*

**OVERVIEW OF THE CANNABIST COMPANY**

The Cannabist Company, formerly known as Columbia Care, is one of the most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 12 U.S. jurisdictions. The Company operates 77 facilities including 61 dispensaries and 16 cultivation and manufacturing facilities, including those under development. Columbia Care, now The Cannabist Company, is one of the original multi-state providers of cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the Company launched Cannabist, its retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including dreamt, Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**SELECTED FINANCIAL INFORMATION**

The following tables set forth selected consolidated financial information derived from our unaudited condensed consolidated interim financial statements and the respective accompanying notes prepared in accordance with U.S. GAAP.

During the periods discussed herein, our accounting policies have remained consistent. The selected and summarized consolidated financial information below may not be indicative of our future performance.

Statement of Operations:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** | **$ Change** | **% Change** | **September 30, 2025** | **September 30, 2024** | **$ Change** | **% Change** |
| Revenues | $79912 | $114783 | $(34871) | (30)% | $253702 | $362584 | $(108882) | (30)% |
| Cost of sales related to inventory production | (57001) | (70973) | 13972 | (20)% | (184353) | (228185) | 43832 | (19)% |
| Gross profit | 22911 | 43810 | (20899) | (48)% | 69349 | 134399 | (65050) | (48)% |
| Fixed asset impairment |  | (121) | 121 | (100)% | (193) | (121) | (72) | 60% |
| Selling, general and administrative expenses | (34941) | (49315) | 14374 | (29)% | (105182) | (142634) | 37452 | (26)% |
| Loss from operations | (12030) | (5626) | (6404) | 114% | (36026) | (8356) | (27670) | 331% |
| Other income / (expense), net | 3709 | 25701 | (21992) | (86)% | (37872) | (1270) | (36602) | 2882% |
| Income tax expense | (6334) | (21838) | 15504 | (71)% | (50349) | (40348) | (10001) | 25% |
| Net loss | (14655) | (1763) | (12892) | 731% | (124247) | (49974) | (74273) | 149% |
| Net profit (loss) attributable to non-controlling interests | (394) | 97 | (491) | (506)% | 99 | 1300 | (1201) | (92)% |
| Net loss attributable to The Cannabist Company Holdings Inc. | (14261) | (1860) | (12401) | 667% | (124346) | (51274) | (73072) | 143% |
| Loss per share attributable to The Cannabist Company Holdings Inc.—based and diluted | $(0.03) | $— | $(0.02) | 623% | $(0.26) | $(0.11) | $(0.14) | 129% |
| Weighted average number of shares outstanding—basic and diluted | 499218628 | $470552039 |  |  | 485743942 | $458988976 |  |  |

---

Summary of Balance Sheet items:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Total Assets | $536509 | $696173 |
| Total Liabilities | $689458 | $726232 |
| Total Long-Term Liabilities | $527329 | $497522 |
| Total Equity | $(152949) | $(30059) |

---

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**RESULTS OF OPERATIONS**

***Comparison of the three and nine months ended September 30, 2025 and 2024***

The following table summarizes our results of operations for the three months ended September 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** | **Three months ended** | **Three months ended** | **Three months ended** |
| | **September 30, 2025** | **September 30, 2024** | **$ Change** | **% Change** |
| Revenues | $79912 | $114783 | $(34871) | (30)% |
| Cost of sales related to inventory production | (57001) | (70973) | 13972 | (20)% |
| Gross profit | 22911 | 43810 | (20899) | (48)% |
| Fixed asset impairment |  | (121) | 121 | (100)% |
| Selling, general and administrative expenses | (34941) | (49315) | 14374 | (29)% |
| Loss from operations | (12030) | (5626) | (6404) | 114% |
| Other income / (expense), net | 3709 | 25701 | (21992) | (86)% |
| Income tax expense | (6334) | (21838) | 15504 | (71)% |
| Net loss | (14655) | (1763) | (12892) | 731% |
| Net profit (loss) attributable to non-controlling interests | (394) | 97 | (491) | (506)% |
| Net loss attributable to The Cannabist Company Holdings Inc. | $(14261) | $(1860) | $(12401) | 667% |
| Loss per share attributable to The Cannabist Company Holdings Inc.—based and diluted | $(0.03) | $— | $(0.02) | 623% |
| Weighted average number of shares outstanding—basic and diluted | 499218628 | 470552039 |  |  |

---

*Revenues*

The decrease in revenue of $34,871 for the three months ended September 30, 2025, as compared to the prior year period, was driven by the net decline in revenue of $13,433 in our existing retail and wholesale operations and a decline of $23,616 from the sale or closure of certain operations. This was partly offset by changes in regulation allowing for adult use which contributed to a revenue growth of $2,178 during the three months ended September 30, 2025, as compared to the prior period.

*Cost of Sales* 

The decrease in cost of sales of $13,972 for the three months ended September 30, 2025, as compared to the prior year period, was driven by a cost of sales decrease from the sale or closure of certain operations of $14,427. This was partly offset by an increase of $455 in our existing retail and wholesale operations, including from inventory impairment.

*Gross Profit* 

The decrease in gross profit of $20,899 for the three months ended September 30, 2025, as compared to the prior year period, was directly attributable to the decline in revenues and the decline in cost of sales as described above.

*Operating Expenses*

The decrease of $14,374 in operating expenses for the three months ended September 30, 2025, as compared to the prior year period, was primarily attributable to decreases in salaries and benefits of expenses of $7,155, operating facilities costs of $2,220, professional fees of $1,644, depreciation and amortization of $1,565, operating office and general expenses of $1,483, and other fees and expenses of $921. This was partially offset by increases in advertisement and promotion expense of $614 for the three months ended September 30, 2025.

*Other Income / (expense), Net*

The increase in other expenses, net of $21,992 for the three months ended September 30, 2025, as compared to the prior year period, was primarily due to increases in loss on disposal group of $52,929, restructuring expense of $112, and other expenses of $776. This was partially offset by decreases in adjustment for held-for-sale of $19,287, change in fair value of the derivative liability of $10,911, interest expense, net of $1,459, interest expense on leases of $157 and a decrease in rental income of $11.

*Provisions for Income Taxes*

The Company recorded income tax expense of $6,334 for the three months ended September 30, 2025, as compared to an income tax expense of $21,838 for the three months ended September 30, 2024.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

The following table summarizes our results of operations for the nine months ended September 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Nine months ended** | **Nine months ended** | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** | **$ Change** | **% Change** |
| **Revenues** | $253702 | $362584 | $(108882) | (30)% |
| Cost of sales related to inventory production | (184353) | (228185) | 43832 | (19)% |
| Gross profit | 69349 | 134399 | (65050) | (48)% |
| Fixed asset impairment | (193) | (121) | (72) | 60% |
| Selling, general and administrative expenses | (105182) | (142634) | 37452 | (26)% |
| Loss from operations | (36026) | (8356) | (27670) | 331% |
| Other income / (expense), net | (37872) | (1270) | (36602) | 2882% |
| Income tax expense | (50349) | (40348) | (10001) | 25% |
| Net loss | (124247) | (49974) | (74273) | 149% |
| Net profit attributable to non-controlling interests | 99 | 1300 | (1201) | (92)% |
| Net loss attributable to The Cannabist Company Holdings Inc. | $(124346) | $(51274) | $(73072) | 143% |
| Loss per share attributable to The Cannabist Company Holdings Inc.—based and diluted | $(0.26) | $(0.11) | $(0.14) | 129% |
| Weighted average number of shares outstanding—basic and diluted | 485743942 | 458988976 |  |  |

---

*Revenues*

The decrease in revenue of $108,882 for the nine months ended September 30, 2025, as compared to the prior year period, was driven by the net decline in revenue of $27,808 in our existing retail and wholesale operations and a decline of $82,537 from the sale or closure of certain

operations. This was partly offset by changes in regulation to adult use which contributed to a revenue growth of $1,463 during the nine months ended September 30, 2025, as compared to the prior period

*Cost of Sales* 

The decrease in cost of sales of $43,832 for the nine months ended September 30, 2025, as compared to the prior year period, was driven by the sale or closure of certain operations of $48,440. This was partly offset by an increase of $4,608 in our existing retail and wholesale operations, including from inventory impairment, as compared to the prior period.

*Gross Profit* 

The decrease in gross profit of $65,050 for the nine months ended September 30, 2025, as compared to the prior year period, was directly attributable to the decline in revenues and the decline in cost of sales as described above.

*Operating Expenses*

The decrease of $37,452 in operating expenses for the nine months ended September 30, 2025, as compared to the prior year period, was primarily attributable to decreases in salary and benefits expenses of $15,852, operating facilities costs of $8,748, depreciation and amortization of $6,156, operating office and general expenses of $3,400, professional fees of $2,778, and other fees and expenses of $1,679. This was partially offset by an increase in advertisement and promotion expenses of $1,161 for the nine months ended September 30, 2025.

*Other Income / (expense), Net*

The increase in other expenses, net of $36,602 for the nine months ended September 30, 2025, as compared to the prior year period, was primarily due to a increases in loss on disposal group of $59,632, interest expense, net of $3,630, and rental income of $56. This was partially offset by decreases in adjustment for held-for-sale of $16,419, change in fair value of investments of $4,391, restructuring expense of $3,326, change in fair value of the derivative liability of $1,970, interest expense on leases of $550, and other expense of $60.

*Provisions for Income Taxes* The Company recorded income tax expense of $50,349 for the nine months ended September 30, 2025, as compared to an income tax expense of $40,348 for the six months ended September 30, 2024.

**Non-GAAP Measures**

We use certain non-GAAP measures, referenced in this MD&A. These measures are not recognized measures under GAAP and do not have a standardized meaning prescribed by GAAP and therefore may not be comparable to similar measures presented by other companies. Accordingly, these measures should not be considered in isolation from nor as a substitute for our financial information reported under

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

GAAP. We use non-GAAP measures including EBITDA, Adjusted EBITDA and Adjusted EBITDA margin which may be calculated differently by other companies. These non-GAAP measures and metrics are used to provide investors with supplemental measures of our operating performance and liquidity and thus highlight trends in our business that may not otherwise be apparent when relying solely on GAAP measures. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for, or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented. We also recognize that securities analysts, investors, and other interested parties frequently use non-GAAP measures in the evaluation of companies within our industry. Finally, we use non-GAAP measures and metrics in order to facilitate evaluation of operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of executive compensation.

The following table provides a reconciliation of net loss for the period to EBITDA and Adjusted EBITDA for the three and nine months ended September 30, 2025, and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
|  | **September 30, 2025** | **September 30, 2024** | **September 30, 2025** | **September 30, 2024** |
| Net loss | $(14655) | $(1763) | $(124247) | $(49974) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax | 6334 | 21838 | 50349 | 40348 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 8055 | 11767 | 24906 | 39314 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net and debt amortization | 11598 | 13127 | 42186 | 38728 |
| EBITDA (Non-GAAP measure) | 11332 | 44969 | (6806) | 68416 |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 552 | 2374 | 1487 | (2588) |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal settlement |  |  |  | (1108) |
| &nbsp;&nbsp;&nbsp;&nbsp;Fair-value changes on investments and derivative liabilities | (6716) | 4195 | 163 | 6524 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments for acquisition and other non-core costs | 3357 | 2393 | 18965 | 10364 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring expense | 1319 | 1207 | 2423 | 5749 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fixed asset impairment |  | 121 | 193 | 121 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) / loss on disposal group | (6803) | (40444) | 3392 | (39821) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA (Non-GAAP measure) | $3041 | $14815 | $19817 | $47657 |
| Revenue | $79912 | $114783 | $253702 | $362584 |
| Adjusted EBITDA (Non-GAAP measure) | $3041 | $14815 | $19817 | $47657 |
| Adjusted EBITDA margin (Non-GAAP measure) | 3.8% | 12.9% | 7.8% | 13.1% |
| Revenue | $79912 | $114783 | $253702 | $362584 |
| Gross profit | $22911 | $43810 | $69349 | $134399 |
| Gross margin | 28.7% | 38.2% | 27.3% | 37.1% |

---

*Adjusted EBITDA*

The decrease in Adjusted EBITDA for the three and nine months ended September 30, 2025, as compared to the prior year period, was primarily driven by declines in gross profit in the ongoing wholesale and retail operations and through restructuring and disposal activity, partially offset by improved leverage of revenues across selling, general, and administrative expenses such as facility costs, salary costs, and benefit costs.

Our future financial results are subject to significant potential fluctuations caused by, among other things, growth of sales volume in new and existing markets and our ability to control operating expenses. In addition, our financial results may be impacted significantly by changes to the regulatory environment in which we operate, on a local, state, and federal level.

**Liquidity and Capital Resources and Going Concern Considerations**

The Company has incurred substantial net losses since its inception, including net losses of $105.1 million for the 12 months ended December 31, 2024 and $124.2 million for the nine months ended September 30, 2025. As of September 30, 2025, the Company's accumulated deficit was $1,309.8 million, and for the nine months ended September 30, 2025, the Company had negative operating cash flow of $35.7 million. As of September 30, 2025, the Company had cash and restricted cash of $20.9 million. Historically, the Company has relied on external financing as its primary source of liquidity. These conditions, together with uncertainty as to the Company's ability to generate sufficient cash flow from operations, asset divestitures or external financing sources to meet its financial obligations including,

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

without limitation, making interest payments on its senior debt or otherwise complying with its indenture obligations, absent material divestitures, significant concessions or consents from its creditors, raise substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date of this report. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. In the future, reports from our independent public accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern.

In an effort to alleviate these conditions and to maximize value for the Company's stakeholders, the Board of Directors (the "Board") has formed a special committee of independent directors (the "Special Committee") to review strategic alternatives. The Special Committee, with support from external financial and legal advisors, is considering a range of options, including potential asset sales, mergers, or other strategic or financial transactions. The review is being conducted in consideration of the ongoing operational and financial challenges for the Company and the industry, as well as of the continuing uncertainty as to if and when U.S. federal regulatory changes may occur that will impact the Company and the industry, including, without limitation, changes to U.S. federal taxation of the Company and the industry under Section 280(e) of the Internal Revenue Code.

If we are unable to obtain sufficient funding or otherwise complete strategic transactions on acceptable terms, or successfully negotiate with creditors with respect to waivers and/or concessions necessary to permit asset divestitures or other actions, then we will not be able to continue as a going concern and we may be forced to delay or further reduce the scope of our activities, extend payment terms with suppliers, liquidate assets where possible at a potentially lower amount than as recorded in our financial statements, further curtail planned operations or cease operations entirely and wind down our business. Any of these could materially and adversely affect our liquidity, financial condition and business prospects and, as a result, our stockholders and/or creditors may not receive full value, or may receive no value, for their investment.

***Recent Financing Transactions***

*2026 Notes*

On February 3, 2022, the Company closed a private placement (the "February 2022 Private Placement") of $185,000 aggregate principal amount of 9.50% senior-secured first-lien notes due 2026 (the "2026 Notes") and received aggregate gross proceeds of $153,250. The 2026 Notes were senior secured obligations of the Company and were issued at 100.0% of face value. The 2026 Notes accrued interest in arrears which was payable semi-annually and were scheduled to mature on February 3, 2026, unless earlier redeemed or repurchased. The Company may redeem the 2026 Notes at par, in whole or in part, on or after February 3, 2024, as more particularly described in the fourth supplemental trust indenture governing the 2026 Notes. In connection with the offering of the 2026 Notes, the Company exchanged $31,750 of the Company's existing 13.0% senior secured first-lien notes (the "13.0% Term Debt"), pursuant to private agreements in accordance with the trust indenture, for an equivalent amount of 2026 Notes plus accrued but unpaid interest and any negotiated premium thereon.

The premium and paid interest were paid out of funds raised from the February 2022 Private Placement. The total unamortized debt premium and debt issuance costs of $2,153, related to the modified portion of the 13.0% Term Debt, was being amortized over the term of the 2026 Notes using the effective interest method. The Company incurred $7,189 in creditor fees in connection with the modified 13.0% Term Debt and 2026 Notes and $301 in third-party legal fees related to 2026 Notes, which were capitalized and were being amortized over the term of the 2026 Notes using the effective interest rate method.

On May 29, 2025, the 2026 Notes were exchanged for the 2028 Notes, see 2025 Debt Transactions (the 2028 Notes and the 2028 Convertible Notes). At the time of the exchange, the remaining unamortized debt premium, debt issuance costs, collector fees, and third party legal fees of $2,216 were written off.

*2027 Convertible Notes*

On March 19, 2024, the Company closed a private placement (the "March 2024 Private Placement") of $25,750 aggregate principal amount of 9.0% senior-secured first-lien notes due 2027 (the "2027 Notes") and received aggregate gross proceeds of $15,600. The 2027 Notes were senior secured obligations of the Company and were issued at 80.0% of face value. The 2027 Notes accrued interest in arrears which was payable semi-annually and were scheduled to mature on March 19, 2027. In connection with the offering of the 2027 Notes, the Company exchanged $5,000 of the Company's existing 6.0% 2025 Convertible Notes. Through September 30, 2025, 983,604 shares were issued to convert $300 principal.

The principal amount of the 2027 Convertible Notes and the conversion price were denominated in U.S. dollars. As the debt was issued out of the Company's Canadian Holding company, but the functional currency of the Company is US Dollars, the amount of the liability to be settled depends on the applicable foreign exchange rate on the date of settlement. The 2027 Convertible Notes therefore represented an obligation to issue a fixed number of shares for a variable amount of liability. Due to this conversion feature within the 2027 Convertible Notes, the Company was unable to obtain an exception from derivative accounting. Accordingly, this conversion feature was accounted for

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

as an embedded derivative liability and measured at fair value of $2,632 on the date of issuance of debt with a corresponding debt discount and debt issuance costs of $5,952, reflected as a reduction to the carrying value of the 2027 Convertible Notes. The Company fair valued the derivative liability at each balance sheet date. Changes in fair value of the embedded derivative were recognized in the condensed consolidated interim statements of operations and comprehensive loss. The debt discount and debt issuance costs were being amortized over the term of the 2027 Convertible Notes.

On May 29, 2025, the 2027 Convertible Notes were exchanged for the 2028 Notes, see 2025 Debt Transactions (the 2028 Notes and the 2028 Convertible Notes). At the time of the exchange, the remaining unamortized debt discount and debt issuance costs of $3,759 were written off.

*2025 Convertible Notes*

On June 29, 2021, the Company completed an offering of 6.0% Secured Convertible Notes Due 2025 ("2025 Convertible Notes") for an aggregate principal amount of $74.5 million. The 2025 Convertible Notes were senior secured obligations of the Company and accrued interest payable semiannually in arrears and were scheduled to mature on June 29, 2025, unless earlier converted, redeemed, or repurchased.

The 2025 Convertible Notes shall be convertible, at the option of the holder, from the date of issuance until the date that is 10 days prior to their maturity date into Common Shares of the Company at a conversion price equal to $6.49 payable on the business day prior to the date of conversion, adjusted downwards for any cash dividends paid to holders of Common Shares and other customary adjustments. The Company may redeem the 2025 Convertible Notes at par, in whole or in part, on or after June 29, 2023, if the volume weighted average price of the Common Shares trading on the Canadian Stock Exchange or Cboe Canada for 15 of the 30 trading days immediately preceding the day on which the Company exercises its redemption right, exceeds 120.0% of the conversion price of the 2025 Convertible Notes at a Redemption Price equal to 100.0% of the principal amount of the 2025 Convertible Notes redeemed, plus accrued but unpaid interest, if any, up to but excluding the Redemption Date.

The 2025 Convertible Notes required interest-only payments until June 29, 2025, at a rate of 6.0% per annum, payable semi-annually in June and December and commencing in December 2021. The 2025 Convertible Notes were scheduled to mature on June 29, 2025. The Company incurred financing costs of $3,190 in connection with the 2025 Convertible Notes. The principal amount of the 2025 Convertible Notes and the conversion price were denominated in U.S. dollars. As the debt was issued out of the Company's Canadian Holding company, but the functional currency of the Company is US Dollars, the amount of the liability to be settled depends on the applicable foreign exchange rate on the date of settlement. The 2025 Convertible Notes therefore represented an obligation to issue a fixed number of shares for a variable amount of liability. Due to this conversion feature within the 2025 Convertible Notes, the Company was unable to obtain an exception from derivative accounting. Accordingly, this conversion feature was accounted for as an embedded derivative liability and measured at fair value of $15,099 on the date of issuance of debt with a corresponding debt discount, reflected as a reduction to the carrying value of the 2025 Convertible Notes. The Company fair valued the derivative liability at each balance sheet date. Changes in fair value of the embedded derivative were recognized in the condensed consolidated interim statements of operations and comprehensive loss. The debt discount was amortized over the term of the 2025 Convertible Notes.

On May 29, 2025, the 2025 Convertible Notes were exchanged for the 2028 Notes, see 2025 Debt Transactions (the 2028 Notes and the 2028 Convertible Notes). At the time of the exchange, the remaining unamortized finance costs of $973, were written off.

*January 2024 Debt Exchange*

On January 22, 2024, the Company entered into an exchange agreement, as amended on June 30, 2024 and September 30, 2024 (the "Exchange Agreement"), with certain holders of the Company's 6.0% senior secured 2025 Convertible Notes (the "Holders"), pursuant to which the Company agreed to the repurchase of up to $25 million principal amount of the 2025 Convertible Notes in exchange for Common Shares (the "January 2024 Debt Exchange").

Pursuant to the terms of the Exchange Agreement, the Holders shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• by January 31, 2024, transfer $5 million principal amount of 2025 Convertible Notes in consideration of Common Shares issued at a price per Common Share equal to the greater of C$0.41 per Common Share and the 12.5% discount to the 5 days volume weighted average price of the Common Shares on Cboe prior to receipt of a Transfer notice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• provided that the five-day volume weighted average price of the Common Shares on the Exchange is greater than C$0.47 as of the close of trading at 4:01pm on January 31, 2024, transfer $5 million principal amount of 2025 Convertible Notes in consideration of Common Shares issued at the Initial Exchange Price on or prior to February 29, 2024; and

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• provided that the February Exchange is completed and the daily volume weighted average price of the Common Shares on Cboe is greater than C$0.87 for 5 consecutive trading days, provided that, the trading volume of the Common Shares on Cboe was equal to or greater than 600,000 Common Shares on the applicable trading dates, from the period commencing on January 1, 2024 and ending on June 30, 2025, (which date the parties extended to December 31, 2024), transfer in three separate equal tranches, an aggregate of $15 million principal amount of 2025 Convertible Notes in consideration of Common Shares issued at a price per Common Share equal to the greater of C$0.57 per Common Share and the 12.5% discount to the 5 days volume weighted average price of the Common Shares on Cboe prior to receipt of a Transfer notice, in each case, subject to adjustment in certain instances, on or prior to December 31, 2024.

Through December 31, 2024, $10 million of the potential $25 million exchange had been completed. The term of the Exchange Agreement expired as of January 31, 2025.

*2025 Debt Transaction (the 2028 Notes and the 2028 Convertible Notes)* 

On February 27, 2025, the Company entered into a support agreement (the "Support Agreement") with certain holders (the "Supporting Noteholders") of the aggregate principal amount of issued Senior Notes (as defined below) regarding the exchange of their Senior Notes for new notes having a later maturity date and additional covenants (the "2025 Debt Transaction"). The Senior Notes consist of: (i) the 2025 Convertible Notes; (ii) the 2026 Notes; and (iii) the 2027 Convertible Notes (together with the 2025 Convertible Notes and the 2026 Notes, the "Senior Notes"). Under the terms of the 2025 Debt Transaction, among other provisions, the holders of the 2025 Convertible Notes and the 2026 Notes exchanged their Senior Notes for an equal principal amount of 9.25% Senior Secured Notes due December 31, 2028 (subject to two six-month extension options available to the Company upon payment of a 0.5% fee, payable in cash) (the new "2028 Notes") and the holders of the 2027 Convertible Notes received either (i) an equal principal amount of the 2028 Notes or (ii) if elected, an equal principal amount of newly issued 9.0% convertible notes, which have the same conversion price as the existing 2027 Convertible Notes but will the same extended maturity date as the 2028 Notes (the new "2028 Convertible Notes", and together with the 2028 Notes, the "New Notes").

The 2028 Notes and 2028 Convertible Notes require interest-only payments until December 31, 2028, payable semi-annually in June and December and commencing in December 2025 until maturity. The Company incurred financing costs of $12,155 in connection with the 2025 Debt Transaction. The principal amount of the 2028 Convertible Notes and the conversion price are denominated in U.S. dollars. As the debt was issued out of the Company's Canadian Holding company, but the functional currency of the Company is US Dollars, the amount of the liability to be settled depends on the applicable foreign exchange rate on the date of settlement. The 2028 Convertible Notes therefore represent an obligation to issue a fixed number of shares for a variable amount of liability. Due to this conversion feature within the 2028 Convertible Notes, the Company is unable to obtain an exception from derivative accounting. Accordingly, this conversion feature was accounted for as an embedded derivative liability and measured at fair value of $230 on the date of issuance of debt with a corresponding debt discount, reflected as a reduction to the carrying value of the 2028 Convertible Notes. The Company fair values the derivative liability at each balance sheet date. Changes in fair value of the embedded derivative are recognized in the condensed consolidated interim statements of operations and comprehensive loss. The debt financing costs are amortized over the term of the 2028 Notes and 2028 Convertible Notes.

In addition, as part of the 2025 Debt Transaction, the Company issued 118,209,105 warrants to the Company shareholders on a pro rata basis, see Note 10 Warrants.

The 2028 Notes and 2028 Convertible Notes are secured by a first-priority security interest in all present and after-acquired personal property of the Company, including a pledge of the Equity Interests owned by the Issuer and each Guarantor; and a collateral assignment of leases in respect of certain leasehold property and all of the Company's interests therein as defined in the Amended and Restated Trust Indenture.

The Company completed its 2025 Debt Transaction effective May 29, 2025 following receipt of court approval.

*Mortgages*

In December 2021, the Company entered into a term loan and security agreement with a bank. The agreement provides for a $20,000 mortgage on real property in New York and carries interest at a variable rate per annum equal to the Wall Street Prime Rate ("Index") plus 2.25%. The debt is repayable in 59 monthly installments and a final balloon payment due on January 1, 2027, which is estimated at $17,907 as of September 30, 2025. In connection with this mortgage, the Company incurred financing costs of $655.

In June 2022, the Company entered into a term loan and security agreement with a bank. The agreement provides for a $16,500 mortgage on real property in New Jersey and carries interest at a variable rate per annum equal to the Index plus 2.25%. The debt is repayable in 59 monthly installments and a final balloon payment due on July 15, 2027, which is estimated at $15,636 as of September 30, 2025. In connection with this mortgage, the Company incurred financing costs of $209.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

On August 10, 2023, the Company entered into two term loans and security agreements with a bank as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The first agreement provides for a $6,250 mortgage on real property in Maryland and carries interest at a variable rate per annum equal to the Index plus 2.25%. The debt is repayable in 59 monthly installments and a final balloon payment due on September 1, 2028, which is estimated at $5,892 as of September 30, 2025. In connection with this mortgage, the Company incurred financing costs of $195 and netted $2,903 after the repayment of a prior outstanding mortgage on the property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The second agreement provides for a $1,800 mortgage on real property in Delaware and carries interest at a variable rate per annum equal to the Index plus 2.25%. The debt was repayable in 59 monthly installments and matures in August 2028. In connection with this mortgage, the Company incurred financing costs of $77 and netted $1,723. The mortgage was paid in full on January 15, 2025 with the sale of the property.

The weighted average interest rate on the Company's indebtedness was 9.23%.

***Cash Flows***

The following table summarizes the sources and uses of cash for each of the periods presented:

---

| | | |
|:---|:---|:---|
| | **Nine months ended** | **Nine months ended** |
| | **September 30, 2025** | **September 30, 2024** |
| Net cash used in operating activities | $(35666) | $(27360) |
| Net cash provided by investing activities | 35459 | 29971 |
| Net cash used in financing activities | (16827) | $(6878) |
| Net decrease in cash | $(17034) | $(4267) |

---

*Operating Activities*

During the nine months ended September 30, 2025, operating activities used $35,666 of cash, primarily resulting from a net loss of $124,247 and a change in fair value of $196, and this was partly offset by deferred income tax of $32,164, depreciation and amortization of $24,906, debt amortization expenses of $11,645, loss on deconsolidation of subsidiary of $3,355, loss on early extinguishment of note of $3,227, provision for credit losses of $3,035, provision for obsolete inventory and other assets of $12,340, equity based compensation of $1,487, change in fair value of derivative liability of $359, impairment of fixed assets of $193, and net decrease in operating assets and liabilities of $3,934. The net change in operating assets and liabilities was primarily due to, a decrease in inventory of $6,800, a decrease in other assets of $9,838, a decrease in accounts receivable of $2,380; this was partially offset by a decrease in accrued expenses and other current liabilities of $4,821, a decrease in accounts payable of $15,494, a decrease in income tax payable of $360, an increase in other long-term liabilities of $1,751, and an increase prepaid expenses and other current assets of $4,028.

During the nine months ended September 30, 2024, operating activities used $27,360 of cash, primarily resulting from a net loss of $49,974, deferred taxes of $2,723, legal settlement of $1,108, gain on deconsolidation of subsidiary of $39,821, and equity-based compensation expense of $2,588; this was partially offset by depreciation and amortization of $39,314, debt amortization expense of $6,794, provision for credit losses of $1,689, provision for obsolete inventory and other assets of $5,671, change in fair value of derivative liability of $2,329, change in fair value of investment of $4,195, other items of $837, impairment of fixed assets of $120, and net increase in operating assets and liabilities of $7,905. The net change in operating assets and liabilities was primarily due to an increase in accounts receivable of $5,095, inventory of $11,566, prepaid expenses and other current assets of $4,255, other assets of $1,388, decrease in accounts payable of $543, and accrued expenses and other current liabilities of $11,281. This was partially offset by an increase in income tax payable of $38,583 and other long term liabilities of $3,450.

*Investing Activities* 

During the nine months ended September 30, 2025, investing activities provided $35,459 of cash, mainly due to the proceeds from the sale of business of $13,957, proceeds from the settlement of note receivables of $21,398, proceeds from the sale of license of $4,100, and cash received on deposits, net of $108. This was partially offset by purchases of property and equipment of $4,104.

During the nine months ended September 30, 2024, investing activities provided $29,971 of cash mainly due to the proceeds from the sale of the Utah, Arizona, and Eastern Virginia businesses of $34,371, and proceeds from sale of license of $329. This was partially offset by purchases of property and equipment of $4,147, cash paid on deposits, net of $268 and change in note receivable of $314.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

*Financing Activities* 

During the nine months ended September 30, 2025, financing activities used $16,827 of cash, mainly due to payment of debt issuance costs of $12,155, payment of lease liabilities of $3,914, repayment of notes payable of $100, repayment of mortgage notes of $526, taxes paid on equity based compensation of $120, and distributions of $12.

During the nine months ended September 30, 2024, financing activities used $6,878 of cash, mainly due to repayments of debt of $13,228, payment of lease liabilities of $5,323, payment of debt issuance costs of $802, repayment of sellers note of $1,119, taxes paid on equity based compensation of $1,255, distributions of $333, and repayment of mortgage notes of $418. This was partially offset by proceeds from issuance of convertible debt of $15,600.

**Contractual Obligations and Commitments**

The following table summarizes contractual obligations as of September 30, 2025 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** |
| | **Total** | **Less than 1 year** | **Year 1** | **Year 2** | **Year 3** | **Year 4** | **Year 5 and beyond** |
| Lease commitments | $219247 | $5798 | $22727 | $22200 | $20025 | $17512 | $130985 |
| Sale-leaseback commitments | 197289 | 2500 | 10212 | 10546 | 10890 | 11247 | 151894 |
| 2028 Notes (principal) | 250750 |  |  |  | 250750 |  |  |
| Interest on 2028 notes | 83373 | 13790 | 23194 | 23131 | 23258 |  |  |
| 2028 Convertible notes (principal) | 19200 |  |  |  | 19200 |  |  |
| Interest on convertible debt | 6211 | 1027 | 1728 | 1723 | 1733 |  |  |
| Mortgage notes (principal) | 40615 | 191 | 815 | 33656 | 5953 |  |  |
| Mortgage notes (interest) | 6862 | 977 | 3858 | 1597 | 430 |  |  |
| Total contractual obligations | 823547 | 24283 | 62534 | 92853 | 332239 | 28759 | 282879 |

---

The above table excludes purchase orders for inventory in the normal course of business.

**Effects of Inflation** 

Rising inflation rates have had a substantial impact on our financial performance to date and may have an impact on our financial performance in the future as our ability to pass on an increase in costs is not entirely within our control.

**Critical Accounting Estimates**

We make judgments, estimates and assumptions about the future that affect assets and liabilities, and revenues and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the review affects both current and future periods.

Judgments, estimates, and assumptions with the most significant effect on the amounts recognized in the consolidated financial statements are described below.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT** 

Our financial instruments consist of cash and cash equivalents, accounts receivable, notes receivable, deposits and other current assets, accounts payable, accrued expenses, current taxes payable and other current liabilities like interest payable and payroll liabilities, derivative liability, debt, and lease liabilities. The fair values of cash and restricted cash, accounts and notes receivable, deposits, accounts payable and accrued expenses and other current liabilities like interest payable and payroll liabilities, short-term debt and lease liabilities approximate their carrying values due to the relatively short-term to maturity or because of the market rate of interest used on initial recognition. The Cannabist Company classifies its derivative liability as fair value through profit and loss (FVTPL).

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The three levels of fair value contained within the hierarchy are:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and

Level 3 – Inputs for the asset or liability that are not based on observable market data.

Our assets measured at fair value on a nonrecurring basis include investments, assets and liabilities held for sale, long-lived assets, and indefinite-lived intangible assets. We review the carrying amounts of such assets whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable or at least annually, for indefinite-lived intangible assets. Any resulting asset impairment would require that the asset be recorded at its fair value. The resulting fair value measurements of the assets are considered Level 3 measurements.

**Financial Risk Management**

We are exposed, in varying degrees, to a variety of financial instrument related risks. Our risk exposures and the impact on our financial instruments is summarized below:

*Credit Risk*

Credit risk is the risk of a potential loss to us if a customer or third party to a financial instrument fails to meet its contractual obligations. The maximum credit exposure at September 30, 2025 and December 31, 2024, is the carrying amount of cash and cash equivalents, accounts receivable and notes receivable. We do not have significant credit risk with respect to our customers. All cash deposits are with regulated U.S. financial institutions.

We provide credit to our customers in the normal course of business and have established credit evaluation and monitoring processes to mitigate credit risk but have limited risk as the majority of our sales are transacted with cash.

*Liquidity Risk*

Liquidity risk is the risk that we will not be able to meet our financial obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure. Our approach to managing liquidity is to estimate cash requirements from operations, capital expenditures and investments and ensure that we have sufficient liquidity to fund our ongoing operations and to settle obligations and liabilities when due.

To date, we have incurred significant cumulative net losses and we have not generated positive cash flows from our operations. We have therefore depended on financing from the sale of our equity and from debt financing to fund our operations. Overall, we do not expect the net cash contribution from our operations and investments to be positive in the near term, and we therefore expect to rely on financing from equity or debt.

*Market Risk*

In addition to business opportunities and challenges applicable to any business operating in a fast-growing environment, our business operates in a highly regulated and multi-jurisdictional industry, which is subject to potentially significant changes outside of our control as individual states as well as the U.S. federal government may impose restrictions on our ability to grow our business profitably or enact new laws and regulations that open up new markets.

*Interest Rate Risk*

Interest rate risk is the risk that the fair value or future cash flows of our financial instrument will fluctuate because of changes in market interest rates. Our cash deposits bear interest at market rates.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

*Currency Risk*

Our operating results and financial position are reported in thousands of U.S. dollars. We may enter into financial transactions denominated in other currencies, which would result in your operations and financial position becoming subject to currency transaction and translation risks.

As of September 30, 2025, and December 31, 2024, we had no hedging agreements in place with respect to foreign exchange rates. We have not entered into any agreements or purchased any instruments to hedge possible currency risks at this time.

*Price Risk*

Price risk is the risk of variability in fair value due to movements in equity or market prices. We are subject to the risk of price variability pursuant to our products due to competitive or regulatory pressures.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

There have been no significant material changes to the market risks as disclosed in the Company's 2024 Form 10-K. See also Financial Risk Management in Part I, Item 2 of this Form 10-Q.

**Item 4. Controls and Procedures.**

*Disclosure Controls and Procedures*

The Company's management, with the participation of the Company's Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that it is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

*Changes in Internal Control*

There were no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) under the Securities Exchange Act of 1934, as amended) during the nine months ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**PART II—OTHER INFORMATION** 

**Item 1. Legal Proceedings.**

Murchinson Ltd., an investment manager of holders of 2025 Convertible Notes and 2027 Convertible Notes (the "Applicant"), filed an application in the Ontario Superior Court of Justice (Commercial List) (the "Court") on March 27, 2025, opposing the 2025 Debt Transaction and claiming the transaction was oppressive to the Applicant. The application filed by the Applicant also claims breach of contract and civil conspiracy. The Applicant seeks from the court, among other forms of relief, that the 2025 Debt Transaction be declared unlawful under the terms of the Canadian Business Corporations Act, an award of unspecified damages, and recovery of costs. By order dated May 21, 2025, the Court ruled in favor of the Company and the 2025 Debt Transaction was subsequently closed. Murchinson Ltd. has filed an appeal to the Court of Appeal for Ontario that is currently pending with a hearing scheduled in February 2026.

**Item 1A. Risk Factors**

Other than set forth herein, there have been no material changes from the risk factors previously disclosed in Part I, Item 1A, of the Company's 2024 Form 10-K, which is incorporated by reference herein.

*The Company may not be able to retain or hire necessary qualified personnel*

The Company's ability to retain or hire qualified personnel is subject to a variety of uncertainties due to the challenging

financial conditions facing both the industry and the Company. If the Company is unable to retain or hire sufficiently

qualified resources, the Company may have difficulty executing on its operational and strategic plans.

**<u>Risks Related to our Financial Condition</u>**

***There is substantial doubt as to our ability to continue as a going concern, and our continuation as a going concern depends on events and circumstances that may not occur.***

Since our inception, we have incurred significant net operating losses, including net losses of $105.1 million for the 12 months ended December 31, 2024 and $124.2 million for the nine months ended September 30, 2025. As of September 30, 2025, the Company's accumulated deficit was $1,309.8 million, and for the nine months ended September 30, 2025, the Company had negative operating cash flow of $35.7 million. As of September 30, 2025, the Company had cash and restricted cash of $20.9 million and debt obligations of $299.3 million. To date, we have financed our operations primarily through external financing as our primary source of liquidity. Our consolidated financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The above conditions, together with uncertainty as to our ability to generate sufficient cash flow from operations, asset divestitures or external financing to meet our financial obligations including, without limitation, making interest payments on our senior debt or otherwise complying with our indenture obligations, absent material divestitures, significant concessions or consents from our creditors, raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of this report.

If we are not able to obtain sufficient funding or otherwise complete strategic transactions on acceptable terms, or successfully negotiate with creditors with respect to waivers and/or concessions necessary to permit asset divestitures or other actions, then we will not be able to continue as a going concern and may be forced to delay or further reduce the scope of our activities, extend payment terms with suppliers, liquidate assets where possible, at a potentially lower amount than as recorded in our financial statements, further curtail planned operations or cease operations entirely and wind down our business. Any such actions could result in significant impairment charges, loss of key personnel, loss of customer relationships, and a material adverse effect on our business, financial condition, results of operations, and prospects. In addition, an inability to continue as a going concern could adversely affect our access to capital and our relationships with vendors, customers, employees and other stakeholders.

***We are reviewing strategic alternatives to reduce leverage and address our capital structure, which may not be successful and could create significant risks and uncertainties.***

The Special Committee, with the assistance of legal and financial advisors, is conducting a comprehensive review of strategic alternatives and is considering a range of options, including potential asset sales, mergers, or other strategic or financial transactions. The review is being conducted in consideration of the ongoing operational and financial challenges for the Company and the industry, as well as of the continuing uncertainty as to if and when U.S. federal regulatory changes may occur that will impact the Company and the industry, including, without limitation, changes to U.S. federal taxation of the Company and the industry under Section 280(e) of the Internal Revenue Code.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

There can be no assurance as to when or whether we will implement any particular transaction or strategy, that any transaction or strategy will be completed on favorable terms or at all, or that any such actions will achieve their intended benefits. Failure to develop and implement effective measures to address our leverage and liquidity could materially and adversely affect our financial condition, business prospects, and ability to refinance debt as it matures or to address potential defaults. Even if we pursue one or more transactions, we may not be able to obtain necessary approvals from stakeholders or regulators, and we may be required to accept terms that are dilutive or not accretive to existing equity holders or otherwise unfavorable.

***Our debt agreements contain covenants that restrict our operations and may inhibit flexibility in operating our business and pursuing strategic alternatives, and failure to comply with these covenants could have a material adverse effect on our business, financial condition and results of operations.***

The indentures governing our 2028 Notes and 2028 Convertible Notes (collectively the "A&R Indenture") contain negative covenants that limit our ability to, among other things, incur additional debt; pay dividends; redeem stock or make other distributions; make investments; create liens; consolidate, merge, sell or otherwise dispose of all or substantially all of our assets; and enter into certain transactions with affiliates.

The A&R Indenture also contains affirmative and financial covenants, including requirements that we: maintain at least $15 million of cash and cash equivalents in accounts subject to control agreements in favor of the trustee; maintain specified Consolidated Leverage Ratios (as defined in the A&R Indenture) as of each fiscal quarter-end commncing March 31, 2026; and obtain Board approval for certain asset sales and the application of related proceeds.

Our obligation to comply with such covenants could decrease our operating flexibility and our ability to achieve our operating objectives, which could have an adverse affect on our business and/or our ability to consummate a strategic transaction. A breach of any covenant or other event of default under the A&R Indenture could, if not cured or waived, result in the acceleration of a substantial portion of our outstanding debt. In such circumstances, we may be unable to access additional liquidity, refinance our debt on acceptable terms, or obtain necessary waivers and/or concessions, and we may not have sufficient cash on hand to repay amounts due. An acceleration could force us to seek bankruptcy protection or other court protection, consummate asset sales on unfavorable terms, or undertake other actions that materially and adversely affect our business, financial condition, results of operations, and prospects. In addition, to implement certain strategic alternatives, such as asset sales, mergers, or other transactions, we may need waivers, amendments, and/or consents from holders of the 2028 Notes and 2028 Convertible Notes, which may not be granted or may be granted only on terms that are unfavorable to us.

**Item 2. Unregistered Sales of Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities.**

Not applicable.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Securities Trading Plans of Directors and Executive Officers

During the three months ended September 30, 2025, none of our directors or executive officers adopted or terminated any contract, instruction, or written plan for the purchase or sale of the Company's securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**Item 6. Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 2.1 | <u>[Arrangement Agreement, dated March 23, 2022, between Cresco Labs Inc. and Columbia Care Inc. (incorporated by reference to Exhibit 2.1 of the Registrant's Current Report on Form 8-K, filed with the SEC on March 29, 2022)](https://www.sec.gov/Archives/edgar/data/1776738/000119312522088069/d292116dex21.htm)</u> |
| 2.2 | <u>[Amending Agreement, dated February 27, 2023, between Cresco Labs Inc. and Columbia Care Inc. (incorporated by reference to Exhibit 2.1 of the Registrant's Current Report on Form 8-K, filed with the SEC on February 28, 2023)](https://www.sec.gov/Archives/edgar/data/1776738/000119312523054004/d469358dex21.htm)</u> |
| 3.1 | <u>[Articles, dated April 26, 2019 (incorporated by reference to Exhibit 3.1 of the Registrant's Form 8-K, filed with the SEC on September 22, 2023)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex31.htm)</u> |
| 3.2 | <u>[Certificate of Change of Name, dated September 19, 2023 (incorporated by reference to Exhibit 3.2 of the Registrant's Form 8-K, filed with the SEC on September 22, 2023)](https://www.sec.gov/Archives/edgar/data/1776738/000119312523239776/d471022dex32.htm)</u> |
| 4.1 | <u>[Warrant Agency Agreement dated September 20, 2018 between Canaccord Genuity Growth Corp. and Odyssey Trust Company (incorporated by reference to Exhibit 4.1 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex41.htm)</u> |
| 4.2 | <u>[Warrant Agreement dated April 26, 2019 between Columbia Care Inc. and Canaccord Genuity Corp. (incorporated by reference to Exhibit 4.2 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex42.htm)</u> |
| 4.3 | <u>[Trust Indenture made as of March 31, 2020 between Columbia Care Inc. and Odyssey Trust Company (incorporated by reference to Exhibit 4.3 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex43.htm)</u> |
| 4.4 | <u>[Warrant Indenture dated March 31, 2020 between Columbia Care Inc. and Odyssey Trust Company (incorporated by reference to Exhibit 4.4 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex44.htm)</u> |
| 4.5 | <u>[Warrant Indenture dated May 14, 2020 between Columbia Care Inc. and Odyssey Trust Company (incorporated by reference to Exhibit 4.6 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex46.htm)</u> |
| 4.6 | <u>[Warrant Indenture dated July 2, 2020 between Columbia Care Inc. and Odyssey Trust Company (incorporated by reference to Exhibit 4.8 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex48.htm)</u> |
| 4.7 | <u>[Warrant Indenture dated October 29, 2020 between Columbia Care Inc. and Odyssey Trust Company (incorporated by reference to Exhibit 4.9 of the Registrant's Registration Statement on Form 10, filed with the SEC on December 14, 2021)](https://www.sec.gov/Archives/edgar/data/1776738/000119312521356939/d252333dex49.htm)</u> |
| 4.8 | <u>[Extension Notice dated March 28, 2023 to Odyssey Trust Company (incorporated by reference to Exhibit 4.14 of the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 29, 2023)](https://www.sec.gov/Archives/edgar/data/1776738/000095017023010606/cchwf-ex4_14.htm)</u> |
| 4.9 | <u>[Amended and Restated Trust Indenture, among The Cannabist Company Holdings Inc. and The Cannabist Company Holdings (Canada) Inc, as co-issuers, and Odyssey Trust Company, as Trustee, dated May 29, 2025 (incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form 8-K, filed with the SEC on June 4, 2025)](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001776738/000110465925056402/tm2517085d1_8k.htm)</u> |
| 4.10 | <u>[First Supplemental Indenture, among The Cannabist Company Holdings Inc. and The Cannabist Company Holdings (Canada) Inc, as co-issuers, and Odyssey Trust Company, dated May 29, 2025 (incorporated by reference to Exhibit 4.2 of the Registrant's Current Report on Form 8-K, filed with the SEC on June 4, 2025)](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001776738/000110465925056402/tm2517085d1_8k.htm)</u> |
| 10.1# | <u>[Summary of The Cannabist Company Holdings Inc. Transaction Bonus Plan (incorporated by reference to Exhibit 10.4 of the Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025)](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001776738/000177673825000038/cbstf-20250630.htm)</u> |
| 10.2# | <u>[Second Amended and Restated At-Will Employment Agreement dated July 17, 2025 between The Cannabist Company Holdings Inc. and Jesse Channon (incorporated by reference to Exhibit 10.5 of the Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025)](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001776738/000177673825000038/cbstf-20250630.htm)</u> |
| 31.1\* | <u>[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](cnstf-20250930xexx311.htm)</u> |

---

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

---

| | |
|:---|:---|
| 31.2\* | <u>[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](cnstf-20250930xexx312.htm)</u> |
| 32.1‡ | <u>[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](cnstf-20250930xexx321.htm)</u> |
| 32.2‡ | <u>[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](cnstf-20250930xexx322.htm)</u> |
| 101.INS\* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB\* | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104\* | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

________________________

\*Filed herewith.

#† Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) of the type that the Registrant customarily and actually treats as private or confidential. The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the SEC.

‡Document has been furnished, is not deemed filed and is not to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in any such filing.

------

<u>[**Table of Contents**](#i50d87a5ec62c4d118a84439d43ce578c_7)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **THE CANNABIST COMPANY HOLDINGS INC.** | **THE CANNABIST COMPANY HOLDINGS INC.** |
| Date: November 10, 2025 | By: | /s/ David Hart |
|  |  | **David Hart** |
|  |  | **Chief Executive Officer** |
| Date: November 10, 2025 | By: | /s/ Derek Watson |
|  |  | **Derek Watson** |
|  |  | **Chief Financial Officer** |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, David Hart, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of The Cannabist Company Holdings Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: November 10, 2025 | By: | /s/ David Hart |
|  |  | **Name: David Hart** |
|  |  | **Chief Executive Officer** |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Derek Watson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of The Cannabist Company Holdings Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: November 10, 2025 | By: | /s/ Derek Watson |
|  |  | **Derek Watson** |
|  |  | **Chief Financial Officer** |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of The Cannabist Company Holdings Inc. (the "Company") on Form 10-Q for the period ending September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: November 10, 2025 | By: | /s/ David Hart |
|  |  | **David Hart** |
|  |  | **Chief Executive Officer** |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of The Cannabist Company Holdings Inc. (the "Company") on Form 10-Q for the period ending September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: November 10, 2025 | By: | /s/ Derek Watson |
|  |  | **Derek Watson** |
|  |  | **Chief Financial Officer** |

---

<br>